

2/12/2020

CURRICULUM VITAE

Massimo Cristofanilli, M.D., F.A.C.P.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor of Medicine, Department of Hematology & Oncology (start date 8/31/2015)
Associate Director of Translational Research and Precision Medicine
Director of the OncoSET Precision Medicine Program
Robert H Lurie Comprehensive Cancer Center
Feinberg School of Medicine

Dual/Joint/Adjunct Appointment

The University of Texas, M D Anderson Cancer Center-4/10-8/10
Adjunct Professor, Temple University College of Science and Technology, Dept. of Biology-2011-2015

CITIZENSHIP

U.S./Italy

OFFICE ADDRESS

Robert H Lurie Comprehensive Cancer Center
710 North Fairbanks Court-Suite 8-250A
Chicago, IL 60611
Phone: 3125035488
Email: Massimo.Cristofanilli@nm.org

EDUCATION

Degree-Granting Education

University La Sapienza, Rome, Italy, MD, 1986, Medicine

Postgraduate Training

Fellowship, Medical Oncology, Oncology Certification with Honors, University La Sapienza, Rome, Italy, 12/1986–11/1990

Fellowship, Clinical Pathology (not completed), University La Sapienza, Rome, Italy, 1/1991–1/1993

Internship, Internal Medicine, Cabrini Medical Center, New York, NY, A. Taranta, MD, 7/1993–6/1994

Resident (PGY-2), Internal Medicine, Cabrini Medical Center, New York, NY, W. Talavera, MD, 7/1994–6/1995

Elective Rotation, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, A.Surbone, MD, 1/1995–6/1995

Chief Resident, Internal Medicine, Cabrini Medical Center, New York, NY, W. Talavera, MD, 7/1995–6/1996

Elective Rotation, Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, L. Gee, MD, 5/1996

Fellowship, Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, Richard Pazdur, MD, 7/1996–6/1998

Methods in Clinical Research 4th Annual Workshop, The University of Texas M. D. Anderson Cancer Center, Vail, CO, 7/1999–8/1999

Program for Chiefs of Clinical Services, Harvard School of Public Health, Boston, MA, 1/2012

CREDENTIALS

Board Certification

Italian Certification in Medical Oncology (cum Laude), 1990

American Board of Internal Medicine, Certification, 1996–2006

European Society for Medical Oncology, Certification, 1999, Recertification Date: 2004

American Board of Medical Oncology, 1999

Recertification Medical Oncology, 2010-2020

Licensures

Active

IL, 336.100606

Inactive

IN, 01046660A, 5/2003

TX, K4032, 1/2006–5/2010

PA, MD439722, 4/2010-12/2014

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/1998–8/2003

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2003–2009

Professor of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 1/2010-12/2012

Professor of Medical Oncology, Thomas Jefferson University/Kimmel Cancer Center, Philadelphia, PA 1/2013-8/2015

Professor of Medicine, Department of Medicine, Division Hematology & Oncology, RH Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 9/2015-Present

Administrative Appointments/Responsibilities

Junior Faculty Associate (JFA), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1998–6/1998

Director, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/2007–2009

Chairman, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 1/2010-5/2012

Leader, Breast Service Line, Fox Chase Cancer Center, Philadelphia, PA 1/2010-12/2012t

Associate Cancer Center Director for Clinical Research, Fox Chase Cancer Center, Philadelphia, PA 1/2010-11/2011

Co-Leader, CCSG Women's Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 1/2010-5/2012

Executive Director and Founder of the Circulating Tumor Cells (CTCs) Center of Excellence- 12/2011-12/2012

Director of Translational Science, Cancer Genome Institute, Fox Chase Cancer Center, 5/2012-12/2012

Deputy Director of Translational Research, TJUH-KCC, 1/2013-8/2015

Director of the Breast Center and Medical Oncology Program, TJUH-KCC, 1/2013-8/2015

Director of the STAR Precision Medicine Program with India, 11/2014 –8/2015
Associate Director of Translational Research: 9/15-present
Director of the Robert Lurie Cancer Center OncoSet Precision Medicine Program: 9/15-present
President of the Inflammatory Breast Cancer International Consortium: 7/15-present
Associate Director of Clinical Research (*ad interim*): 4/16-9/16
Director of the Breast Disease Team: 4/17-present
President of the International Society of Liquid Biopsy (ISLB): 9/18-present
Chair of the Oversight Committee of the Precision Medicine Exchange Consortium (PMEC): 9/2017-
Current

Other Appointments/Responsibilities

Attending Physician, Villa Margherita, Hospital, Rome, Italy, 4/1988–5/1993
Medical Oncology, Voluntary Service, University La Sapienza, Rome, Italy, 12/1990–5/1993

Endowed Positions

G. Morris Dorrance Jr. Endowed Chair in Medical Oncology Fox Chase Cancer Center, Philadelphia, PA
1/2010-12/2012

Consultantship

Dompe Pharmaceutical, 6/2010-12/17 (Advisory Board)
Alere dx: 1/2010-12/2013
Agendia : 9/2014 to 8/15
Nanostrings: 10/2014 to 12/2015
AstraZeneca Pharmaceuticals, Consultant, 1/2009–12/2010
Merck, Breast Tumor Strategy Committee, 2/2009–12/2012
Merch- Chair Breast DMC 9/26/16-current
EMD Serono, Houston, Consultant, 5/2009–5/2010
Foundation Medicine 04/12-3/13
Newomics 6/12-12/17 (Advisory Board)
Vortex 6/16- 2/18 (Chair Scientific Advisory Board)
G1 Therapeutics, Consultant, 6/2017-current
Merus 8/17-12/18 Consultant
Zeno Pharmaceutical: 9/17-10/18: Consultant
Novartis Pharmaceutical: 10/17-12/18: consultant
CytoDyn: 9/18-current (advisory Board)
AZ- Chair IDMC-CAPItello study- 5/19-current

Military or Other Governmental Service

N/A

Institutional Committee Activities

Pharmacy and Therapeutics Subcommittee, Representative, The University of Texas, M D Anderson
Cancer Center, 1998–2001

Clinical Research Committee (CRC), Representative, The University of Texas, M D Anderson Cancer Center, 2002–2004

Study Section Review Committee for Basic Research Projects under the Institutional Research Grants Program, Representative, The University of Texas, M D Anderson Cancer Center, 2002–2005

Phase I Research Working Group, Representative, The University of Texas, M D Anderson Cancer Center, 2003–2005

Breast Cancer Tissue Bank Committee, Member, The University of Texas, M D Anderson Cancer Center, 2003–2005

Preclinical Working Group, Member, The University of Texas, M D Anderson Cancer Center, 2004–2005

Institutional Research Grant (IRG) Review Panel, Member, The University of Texas, M D Anderson Cancer Center, 2004–2006

Clinical Research Subcommittee for Faculty Achievement Award, Member, The University of Texas, M D Anderson Cancer Center, 1/2004–12/2004

Clinical Research Committee (CRC 1), Member, The University of Texas, M D Anderson Cancer Center, 1/2006–9/2009

Selection Committee for the 3rd AACR Outstanding Investigator Award for Breast Cancer Research, 2010

Executive Committee of Staff (ECOS), Member, Fox Chase Cancer Center, 2010–2012

Executive Committee of Research (ECOR), Member, Fox Chase Cancer Center, 2010 – 2012

Clinical Council, Member, Fox Chase Cancer Center, 2010 – 2012

Faculty Practice Plan Executive Council, Member, Fox Chase Cancer Center, 2010 – 2012

Revenue Enhancement Committee, Fox Chase Cancer Center 2010 – 2012

Integrative Care Initiative Committee, Fox Chase Cancer Center 2011 – 2012

Corporate Agenda Planning Committee, Fox Chase Cancer Center 2011 – 2012

Metastatic Breast Cancer Working Group, WCP at the Fox Chase Cancer Center 2011 –10/2012

Clinical Research Task Force, Leader, Fox Chase Cancer Center, 2011 – 2012

Clinical Research Committee- Fox Chase Cancer Center- 2/2010-12/2012

Executive Leadership Committee-Kimmel Cancer Center: 2013-2015

Comprehensive Status Program- KCC; 2014-2015

Executive Leadership Committee-Robert Lurie Cancer Center-9-15-current

CRO Governance Committee-RLCC: 9/15-current

Cancer Center Executive Council-RLCC: 9/15-current

Member of the Quantitative and Data Science Core Advisory Committee

Member of the Proteomic Core Advisory Committee

Extramural Activities

Funder of the IBC International Consortium (IBC-IC)

Chair of the Precision Medicine Exchange Consortium (PMEC) Oversight Committee: 9/17-Present

President of the IBC-IC

Chair of the Admission Committee of the International Society of Liquid Biopsy (ISLB): 8/17-Present

President of the International Society of Liquid Biopsy: 8/18-Present

ODAC-FDA Committee-Standing Membership: 7/2018-current
Chair of the Merck Breast DMC- 10/2018-Present
G1 Therapeutic Steering Committee: 5/18-present
Sermonix- Steering Committee: 5/19-present
AZ- Chair IDMC-CAPitello study- 5/19-current

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

Italian Association of Medical Oncology, Italy

Member, 1987–present

Italian Society of Immunology, Oncologic Embriology, Italy

Member, 1987–1993

Italian Society of Palliative Care, Italy

Member, 1990–1993

European Association of Cancer Research (EACR), United Kingdom

Member, 1998–present

International Society of Preventative Oncology, United Kingdom

Member, 1998–2002

American Association for Cancer Research (AACR), PA

Member, 1999–present

American Society of Clinical Oncology (ASCO), VA

Member, 2000–present

American Society of Surgical Oncology (ASSOG) Group, TX

Member, 2000–present

European Society Medical Oncology (ESMO), Switzerland

Member, 2000–present

European Society of Breast Imaging, Austria

Member, 2000–present

Southwest Oncology Group (SWOG), MI

Member, 2000–2010

American Society of Gene Therapy, WI

Member, 2003–2009

American Society of Breast Disease

Member, 2005–present

Eastern Cancer Cooperative Group (ECOG)- Breast Committee

Member 2010-present

The Biomarkers Consortium
Foundation for the National Institutes of Health (NIH) - Member
2009-present
AAAS member 2012-2019
ASCO Biomarkers Expert Panel-Member 2012-2013
American Council of Science and Health-Advisory Board Member, 3/17-Present
International Society of Liquid Biopsy- Chair Nominating Committee-4/17-Present

HONORS AND AWARDS

Clinical Appreciation Certificate for significant clinical skills course, New York Medical College, 1996
Clinical Fellow Research Award, The University of Texas M. D. Anderson Cancer Center, 1998
Fellow, American College of Physician (FACP), 2003
Outstanding Educator, The University of Texas M. D. Anderson Cancer Center, 2003
“Cavaliere del Lavoro” (Knight of the Italian Republic) for outstanding scientific contribution- Italian Republic- 2006
Distinguished Alumnus Award, The University of Texas M. D. Anderson Cancer Center, 2008
US News & World Report- Best Doctor- 2009-present
ASCO 2011 Humanitarian Award Finalist
Philadelphia Magazine Best Doctor-2012
Giovanni Giacomo Giordano NIAF Lifetime Achievement Award for Ethics and Creativity in Medical Research-2012
Scientific Research Award, American Cancer Society, Southeast Region – 10-2012
3rd Annual Jamie Brooke Lieberman Remembrance Award- Philadelphia 2015
IBC Foundation Impact Award, Chicago 2016
2017 Morgan Welch Inflammatory Breast Cancer Ambassador Award, Houston, 2017
BJ Club-Best Breast Cancer Scientific Paper 2016- March 10-11, 2017, Naples

RESEARCH

Grants and Contracts (past 5 years)

FUNDED

Program Leader, 2.0 months, Comprehensive Cancer Center Program at Fox Chase P30 CA006927
9/2011 – 06/30/2014

Co-Program Leader, 2.4 months, Novel targets for treatment and detection of inflammatory breast cancer, KGO71287, Susan G. Komen Breast Cancer Foundation, PI - Robertson, 3/1/2008–2/28/2013, \$7,500,000 (\$1,500,000/year)

Principal Investigator, 0.6 months, Human breast cancer stem cell surrogates, 1 R01 CA138239-02, NIH/NCI, 9/25/2008–7/31/2013, \$465,744 (\$93,028/year)

Co-Investigator, 0.12 months, Eradication of breast cancer minimal residual disease with a bisphosphonate and a COX-2 inhibitor, NIH/NCI, PI - Lucci, 12/1/2009–11/30/2014, \$1,737,500 (\$347,500/year)

Collaborative Research Agreement 11/30/15 – 11/29/17

Falk Foundation Grant (PI: Richard Pestell)
Targeting CCR5 in Cancer Treatment
The goal of this project is to test a combination of CCR5-inhibitor combined with chemotherapy.
Role: PI

ACTIVE

P30CA060553 (Platanias) 09/01/13-07/31/18
NIH/NCI
The Robert H. Lurie Comprehensive Cancer Center
Role: Associate Director, Precision Medicine and Translational Science

P30CA060553 (Platanias) 09/01/13-07/31/18
NIH/NCI
The Robert H. Lurie Comprehensive Cancer Center
Career Development Funds
Role: Career Development Awardee

R01CA207468 (Yang) 09/01/17-08/31/22
NIH
A population-based approach to single CTC analysis in metastatic breast cancer outcome
Role: Sub-PI

1UG3OD023189-01 (Greenland/Ahsan/Winn/Daviglus) 07/06/16 - 12/31/21
NIH/Office of Director
Illinois Precision Medicine Consortium (IPMC)
This is a collaborative multi-PI, multi-site application from the Illinois Precision Medicine Consortium to serve as a Precision Medicine Initiative Cohort Program healthcare provider organization (HPO) Enrollment Center in response to RFA-PM-16-002. Role: Co-Investigator

METAVIVOR Founders Award: “Unravelling New Cytokine-Mediated Mechanisms to Enhance Response to CDK4/6 inhibition in ER+/HER2- Metastatic Breast Cancer” 2/20-1/2023. Role: PI

COMPLETED:

Co-Program Leader: Cynvenio Biosystems Inc. SBIR Phase II Topic 293: Developing predictive biomarkers in metastatic breast cancer using liquid biopsy. HHSN261201300073C. 08/27/14-8/26/15; \$30,500. (0.12 calendar)

DOD-DARPA(Tang): Study of a Newly Discovered Immune Cell in the Blood and Evaluation of Its Potential Medical Applications. Sub from Creatv Microtech, Inc. 7/15/14-7/14/16. \$48,000. (0.48 calendar)

NIH(Tang). Circulating Giant Macrophages in MBC: a novel prognostic biomarker of metastasis. Sub from Creatv MicroTech, Inc. 12/01/14-11/30/15. (.6 calendar).

NIH (Shih): Low Cost Blood Molecular Malignancy Test to Detect Recurrences of Breast Cancer. Sub from Lenima. 4/1/15-3/31/16. (1.2 calendar).

Co-Investigator, 0.6 months, Assessing drug response and prognosis in breast cancer using AAVP-based targeted molecular-genetic imaging, Department of Defense (DOD), PI - Arap/Pasqualini, 6/1/2009–6/30/2014, \$6,939,285 (\$1,387,857/year)

Co-Investigator, 0.6 months, Bioengineering and clinical applications of circulating tumor cell chip, The General Hospital Corporation, PI - Herbst, 8/1/2009–7/31/2011, \$1,800,000 (\$450,000/year)

Collaborator, 0.6 months, Gene expression signature of early breast cancer, no cost extension, CA84978-01A1, NIH, PI - Aldaz, 4/6/2001–3/31/2006, \$4,666,942 (\$1,166,735/year)

Collaborator, 0.6 months, Novel technologies for mapping vascular diversity of human cancer, no cost extension, R33 CA103030-01, NIH/NCI, PI - Arap, 3/15/2004–2/28/2007, \$450,537 (\$150,179/year)

Collaborator, 0.6 months, Spousal relationships and pain in metastatic breast cancer, no cost extension, W81XWH-04-1-0425-02, Department of Defense (DOD) U.S. Army Medical Research and Material Command Congressionally Directed Medical Research Programs, PI - Badr, 8/25/2004–9/24/2007, \$404,892 (\$134,964/year)

Collaborator, Regulatory roles for vascular peptidases in angiogenesis, no cost extension, HL081658, NIH/NCI, PI - Pasqualini, 8/1/2005–7/31/2009, \$250,000 (\$50,000/year)

Principal Investigator, 0.12 months, Creation of the rare and aggressive breast cancer, no cost extension, State of Texas, 9/1/2007–8/31/2011, \$4,000,000 (\$2,000,000/year)

Principal Investigator, 0.6 months, Magnetic resonance imaging (MRI) for evaluation of clinical response to induction chemotherapy in breast cancer, CS00-098-1, Susan G. Komen Breast Cancer Foundation, 12/30/1999–6/30/2005, \$244,300 (\$48,860/year)

Collaborator, 0.6 months, The prospective validation of soluble isoforms of ErbB2 (p105-sErB2) and EGFR (110kD-sEGFR) as serum markers of efficacy in hormone sensitive postmenopausal women with metastatic breast cancer treated with either anastrozole alone or in combination with ZD1839 (IRESSA), CA096300005, PRCC/MDACC, PI - Cora, 8/16/2002–7/31/2007, \$30,000 (\$30,000/year)

Principal Investigator, 0.6 months, Phase II trial of depsipeptide in metastatic breast cancer, CA 70172, NCI/CTEP-U01, 8/1/2005–7/31/2007, \$50,000 (\$25,000/year)

Principal Investigator, 0.12 months, First international inflammatory breast cancer conference, 1R13 00451843, NIH/NCI, 12/5/2008–2/28/2010, \$6,450 (\$6,450/year)

Principal Investigator, 0.12 months, Development of Gamma-Secretase inhibitor (R4733) in inflammatory breast cancer, Hoffman-LaRoche, 2/1/2009–1/31/2010, \$75,504 (\$75,504/year)

Program Leader, 2.0 months, Comprehensive Cancer Center Program at Fox Chase P30 CA006927 10/2005 – 06/30/2011

Principal Investigator, 0.12 months, Human breast cancer stem cell surrogates, NCI-APRC 3R01CA138239-02S1, NIH/NCI, 9/30/2009–9/29/2011, \$537,966 (\$268,983/year)

PROTOCOL/contracts

NU16B06: Blood-based prognostic biomarkers of Breast Cancer patients

NU-16B14: I-CURE-1: A phase II, multicenter, single arm study of pembrolizumab combined with carboplatin in patients with circulating tumor cells (CTCs) positive metastatic breast cancer (MBC);

NU16B09: A Phase II, open-label study to evaluate denosumab in patients with ER and/or PR positive, HER2 negative metastatic breast cancer (MBC) with bone metastases and detectable circulating tumor cells (CTCs)

NU15B01: A single arm, Phase II study evaluating the efficacy and safety of MED14736 in combination with tremelimumab in patients with metastatic HER2 negative breast cancer

NUDF17B11: Palbociclib after CDK and endocrine therapy (PACE): A randomized Phase 2 study of fulvestrant: Palbociclib and Avelumab for endocrine-retreated ER+/HER2 – MBC

NU18B04: MONARCH-PRECISION PROGRAM : A Prospective, Multicenter, Randomized, Open Label, Phase II study of Abemaciclib combined with fulvestrant vs. abemaciclib in patients with molecularly defined subtypes of hormone-receptor positive (HR+), HER-2 negative MBC

DRUG CD07_TNBC: A Phase Ib/II Study of Leronlimab (PRO 140) Combined with Carboplatin in Patients with CCR5+ Metastatic Triple-Negative Breast Cancer (mTNBC)

DRUG DCC-2036-01-003: An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors

NUDB 16Z01: The OncoSET Program Database and Biobank - Combining Clinical Outcomes with Next Generation Sequencing and other Advanced Molecular Testing for Genetic Aberrations in Patients with Advanced Solid Malignancies

Funded/Completed

Principal Investigator, Multimodality approach in the treatment of inflammatory breast carcinoma (IBC), DM98-087, 1999–2000, \$180,000 (\$180,000/year), Bristol Myers Squibb

Principal Investigator, Phase II study of RFS 2000 (9-Nitro-Camptothecin) in recurrent metastatic breast cancer, DM99-235, 1999–2005, \$172,000 (\$34,400/year), SuperGen, Inc.

Principal Investigator, Isolation and enumeration of malignant cells from the peripheral blood of patients with advanced breast cancer, ID99-391, 2001–2003, \$374,940 (\$187,470/year), Immunicon

Principal Investigator (Investigator-initiated), Phase II single arm, single institution clinical trial of Docetaxel and Doxorubicin in combination with local administration of AD5CMV-p53 (RPR/INGN 201) in locally advanced breast cancer, ID00-008, 2001–2005, \$540,000 (\$180,000/year), Introgen Therapeutics, Inc.

Principal Investigator (Investigator-initiated), Phase II trial of PS-341 in metastatic breast cancer, ID00-308, 2002–2003, \$25,000 (\$25,000/year), NCI/CTEP, Translational Research Fund (TRF)

Principal Investigator, Tc99-EC-Annexin-V for imaging of apoptosis: A bio-distribution study in primary breast cancer, ID-02-732, 2002–2003, \$130,865 (\$130,865/year), CellPoint, LCC

Principal Investigator (Investigator-initiated), Phase II trial of STI571 in metastatic breast cancer, ID01-691, 2003–2004, \$75,000 (\$75,000/year), NCI/CTEP, Translational Research Fund (TRF)

Principal Investigator, International stage IV stratification study (ISSS): Prospective validation trial of circulating tumor cells (CTCs) as prognostic and predictive markers in women with metastatic breast cancer about to start first-line treatment, 2005-0278, 2004–2005, \$200,000 (\$200,000/year), Veridex, LLC

Principal Investigator (Investigator-initiated), Phase II multicenter, double blind, randomized trial comparing anastrozole (ZD1033), ARIMIDEX™ placebo to the combination Anastrozole ZD1839 (Gefitinib, Iressa™) in postmenopausal patients with estrogen receptor (ER) and/or progesterone receptor (PGR), 2003-0587, 2004–2007, \$308,060 (\$308,060/year), AstraZeneca

Principal Investigator, A multicenter, open label, phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in patients with relapsed or refractory inflammatory breast cancer, 2004-0831, 2005–2008, \$237,556 (\$79,185/year), GlaxoSmithKline

Principal Investigator, A randomized, multicenter, phase III study comparing the combination of Pazopanib and Lapatinib versus Lapatinib monotherapy in patients with ErbB2 overexpressing inflammatory breast cancer, 2007-0448, 2007–2009, GlaxoSmithKline

Principal Investigator (Investigator-initiated), A phase I-II study of R115777 (Tipifarnib, Zarnestra) plus sequential weekly paclitaxel followed by dose-dense doxorubicin and cyclophosphamide in patients with stage IIB-IIIC breast cancer, 2007-0766, 2008–2009, \$52,101 (\$52,101/year), NCI/CTEP

Principal Investigator (Investigator-initiated), A phase II study of neoadjuvant Lapatinib plus chemotherapy (sequential FEC75 and paclitaxel) in women with inflammatory breast cancer whose tumors overexpress ErbB2 (Her2/neu), 2007-0818, 2008–2010, \$497,701 (\$248,850/year)

Principal Investigator, Determination of HER2 tumor status by circulating tumor cell (CTC) analysis, LAB06-0975, 2008–2010, \$39,306 (\$19,653/year), Genentech

Principal Investigator (Investigator-initiated), Prospective trial of circulating tumor cells by a polymerase chain reaction based technique (AdnaGen Breast Test) in women with high-risk locally advanced breast cancer that have completed neoadjuvant and local therapy, LAB08-0159, 2012, Alere

Principal Investigator. A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 in Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopausal Women with Hormone Receptor-positive, Endocrine Therapy-Naïve, Locally-advanced or Metastatic Breast Cancer (MINT)., 2012-AZ

Principal Investigator. An open label multicenter phase 2 window of opportunity study evaluating ganetespib (STA-9090) monotherapy in women with previously untreated metastatic HER-2 positive or triple negative breast cancer, 2012, Synta

Principal Investigator (Investigator-initiated). A Phase 1/2 Study of Romidepsin in Combination with Abraxane in Patients with HER-2 neg, Metastatic Inflammatory Breast Cancer (IBC)- 2012- Celgene Corporation

Sub-investigator. IRB-11007: A Phase I, Multicenter, Open-Label Dose Escalation Study of LDK378, Administered Orally In Adult Patients with Tumors Characterized by Genetic Abnormalities In Anaplastic Lymphoma Kinase (ALK)- 2011-2012-Novartis

Principal investigator (Investigator-initiated). IRB 10-826: prospective collection of Tumor specimens for the establishment of Inflammatory Breast Cancer (IBC) cell lines. Susan Komen Foundation

Principal investigator (Investigator-initiated): NU16B06: Blood-based prognostic biomarkers of Breast Cancer patients (OncoSET Program)

Principal investigator (Investigator-initiated).NU-16B14: I-CURE-1: A phase II, multicenter, single arm study of pembrolizumab combined with carboplatin in patients with circulating tumor cells (CTCs) positive metastatic breast cancer (MBC)-Merck

Principal investigator (Investigator-initiated).NU16B09: A Phase II, open-label study to evaluate denosumab in patients with ER and/or PR positive, HER2 negative metastatic breast cancer (MBC) with bone metastases and detectable circulating tumor cells (CTCs)-Amgen

Principal investigator (Investigator-initiated).NU16B07: A Phase 2 window-of opportunity trial of ipilimumab and nivolumab in metastatic, recurrent HER2- inflammatory breast cancer (IBC). The WIN TRIAL-BMS

Principal investigator (Investigator-initiated).NU16B: I-TARGET IBC: A prospective, single arm, Phase 2 study of nab-paclitaxel (abraxane) combined with alpelisib BYL719 following anthracycline-based regimen in patients with primary HER-2-IBC-Novartis

Principal investigator (Investigator-initiated) NU17: I-STOP: A Phase Ib-II, multicenter, single arm study of Maraviroc combined with carboplatin in patients with CCR5+ triple negative metastatic breast cancer (MBC)-CytoDyn

Unfunded by Peer Review Grant (supported by Texas State Grant)

Principal Investigator, Inflammatory breast cancer (IBC) registry, 2006-1072, 2007–2009

Patents and Technology Licenses

Patents

- Immunivest Corp., Allard JW, Cristofanilli M, Terstappen LWMM. Circulating cancer cells: Early assessment of time to progression survival and response to therapy in metastatic breast cancer, United States, 60/450,519, 10/9/2004, Issued
- The Scripps Research Institute, Blixt O, Cristofanilli M, Huflejt ME. Detection, prevention and treatment of breast cancer, United States, 60/629,666, 11/12/2004, Issued
- Board of Regents, The University of Texas System co-owns with Introgen Therapeutics, Inc., Cristofanilli M, Krishnamurthy S, Menander K, Hortobagyi GN. Cancer immunotherapy incorporating p53, United States, 60/628,990, 11/17/2004, Issued
- Board of Regents, The University of Texas System, Cristofanilli, Mani, Reuben. Detecting EMT markers for circulating cancer stem cells. International application W2011/111103 A2
- Board of Regents, The University of Texas System, Fox Chase Cancer Center, Celgene corp. Romidepsin for the reprogramming and treatment of IBC. Filed 4/12
- CCR5 as metastatic target in CTCs in TNBC, TJU-Richard Pestell.

Technology Licenses

Co-Founder of Cirtec diagnostics (Reuben, Mani, Ravi) – pending license

Grant Reviewer/Service on Study Sections

Italian Association for Cancer Research, Grants, Grant reviewer, 2002

Cancer Research UK, Grants, Grant reviewer, 2005

CBCRA Metastases Grant Applications - Competition, CCRA grants, Site Visitor, 2005

Italian Association for Cancer Research, Grants, Grant Reviewer, 2005

DOD-Era of Hope, Abstract Reviews, DOD, Abstract reviewer, 2005-present

NIH, Study Review Section for Minorities, Grants, Grant Reviewer, 2009-present

San Antonio Breast Cancer Symposium, Abstract Reviewer, Abstracts, Reviewer, 2009-present

The Susan G. Komen Foundation, Promise Grants, Scientific Reviewer, 2009-2010

NIH, Study Review Section, SBIR, Panel Member, 2010-present

The Susan G. Komen Foundation, 2015-current

PUBLICATIONS (H index-87)

Peer-Reviewed Original Research Articles

1. Cristofanilli M, Bryan WJ, Miller LL, Chang AY, Gradishar WJ, Kufe DW, Hortobagyi GN. Phase II study of adozelesin in untreated metastatic breast cancer. *Anticancer Drugs* 9:779-82, 1998.
2. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. *Cancer Treat Rev* 25:271-7, 1999.
3. Cristofanilli M, Holmes FA, Esparza L, Valero V, Buzdar AU, Neidhart JA, Hortobagyi GN. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: The M. D. Anderson Cancer Center experience. *Breast Cancer Res Treat* 54:225-33, 1999.
4. Younes A, Cristofanilli M, McLaughlin P, Hagemester FB, Weber D, Mesina O, Cabanillas F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. *Leuk Lymphoma* 40:79-85, 2000.
5. Kushwaha AC, Whitman GJ, Stelling CB, Cristofanilli M, Buzdar AU. Primary inflammatory carcinoma of the breast: Retrospective review of mammographic findings. *AJR Am J Roentgenol* 174:535-8, 2000.

6. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. *J Clin Oncol* 19(8):2240-6, 2001.
7. Whitman GJ, Kushwaha AC, Cristofanilli M, Dempsey PJ, Slack HK, Stelling CB. Inflammatory breast cancer: Current imaging perspectives. *Semin Breast Dis* 4(3):122-131, 2001.
8. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. *Cancer* 92(7):1775-82, 2001.
9. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. *J Clin Oncol* 19:2587-95, 2001.
10. Rivera E, Valero V, Cristofanilli M, Frye DK, Booser DJ, Rosales MM, Hortobagyi GN. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. *Cancer* 94(9):2321-6, 5/2002.
11. Cristofanilli M, De Gasperis G, Zhang L, Hung MC, Gascoyne PR, Hortobagyi GN. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. *Clin Cancer Res* 8:615-9, 2002.
12. Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. *Cancer Chemother Pharmacol* 49(4):299-302, 2002.
13. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. *Semin Radiat Oncol* 12:319-28, 2002.
14. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. *J Clin Oncol* 20:1800-8, 2002.
15. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. *Clin Cancer Res* 9(7):2426-34, 2003.
16. Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. *Cancer* 98(5):900-7, 2003.
17. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. *Cancer J* 9(1):33-41, 2003.
18. Chagpar A, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames FC, Marcy S, Babiera GV, Feig BW, Hortobagyi GN, Kuerer HM. Chest wall recurrence after mastectomy does not always portend a dismal outcome. *Ann Surg Oncol* 10(6):628-34, 2003.
19. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. *Nat Biotechnol* 21:57-63, 2003.
20. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. *Clin Cancer Res* 9:2406-15, 2003.

21. Kuerer HM, Thompson PA, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, Singletary SE, Cristofanilli M, Sneige N, Hunt KK. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. *Clin Cancer Res* 9:601-5, 2003.
22. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27 (Kip1) levels in node-negative breast cancer. *Clin Cancer Res* 9:5652-9, 2003.
23. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM. Nipple aspirate fluid cytology in breast carcinoma. *Cancer* 99(2):97-104, 2003.
24. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. *Oncologist* 8(2):141-8, 2003.
25. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. *Cancer* 101:1760-6, 2004.
26. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 351:781-91, 2004.
27. Shen J, Valero V, Buchholz TA, Singletary SE, Ames FC, Ross MI, Cristofanilli M, Babiera GV, Meric-Bernstam F, Feig B, Hunt KK, Kuerer HM. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. *Ann Surg Oncol* 11:854-60, 2004.
28. Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. *Breast J* 10(4):323-7, 2004.
29. Krishnamurthy S, Zhao L, Hayes K, Glassman AB, Cristofanilli M, Singletary SE, Hunt KK, Kuerer HM, Sneige N. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. *Cancer* 102(5):322-7, 2004.
30. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M. p53 expression as a prognostic marker in inflammatory breast cancer. *Clin Cancer Res* 10(18 Pt 1):6215-21, 2004.
31. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M. D. Anderson Cancer Center experience. *Clin Breast Cancer* 4(6):415-9, 2004.
32. Resetskova E, Gonzalez-Angulo AM, Sneige N, McDonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. *Cancer* 101(5):913-7, 2004.
33. Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. *Mod Pathol* 18(9):1165-75, 2005.
34. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res* 11(16):5678-5685, 2005.
35. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. *Clin Cancer Res* 11(9):3309-14, 2005.
36. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. *J Clin Oncol* 23(7):1420-30, 2005.

37. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Combined-modality treatment for isolated recurrences of breast carcinoma: Update on 30 years of experience at the M. D. Anderson Cancer Center and assessment of prognostic factors. *Cancer* 104(6):1158-1171, 2005.
38. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. *Cancer* 104(4):676-81, 2005.
39. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. *J Clin Oncol* 23(28):7098-104, 2005.
40. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. *J Clin Oncol* 23(1):41-8, 2005.
41. Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. *Cancer* 104(3):479-90, 2005.
42. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. *Clin Cancer Res* 11(9):3315-9, 2005.
43. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol* 23(16):3676-85, 2005.
44. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear transcription factor kappa B (NF-kB) and bcl-2 pathway correlates with pathological complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. *Clin Cancer Res* 11(23):8398-8402, 2005.
45. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma: Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. *Cancer* 103(6):1122-8, 2005.
46. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. *J Clin Oncol* 23(25):5983-5992, 2005.
47. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: Safety, efficacy, and biologic activity of a novel gene-therapy approach. *Cancer* 107(5):935-44, 2006.
48. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M. Biologic markers in axillary node-negative breast cancer: Differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. *Clin Breast Cancer* 7(4):396-400, 2006.
49. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib (VELCADE®) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits. *Ann Oncol* 17:813-817, 2006.

50. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. *Clin Cancer Res* 12(14 Pt 1):4218-24, 2006.
51. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating tumor cells versus imaging: Predicting overall survival in metastatic breast cancer. *Clin Cancer Res* 12(21):6403-9, 2006.
52. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. *Cancer* 106(5):1000-1006, 2006.
53. Gonzalez-Angulo AM, Guarneri V, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. *Clin Breast Cancer* 7(4):326-30, 2006.
54. Andre F, Cabioglu N, Assi H, Sabourin JC, Delalogue S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. *Ann Oncol* 17(6):945-951, 2006.
55. Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondón G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. *Bone Marrow Transplant* 37(10):929-935, 2006.
56. Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi GN, Mettinger KL, Cristofanilli M. Minimal benefit of single agent Orathecine (Rubitecan) in heavily pretreated metastatic breast cancer. *Cancer Chemother Pharmacol* 57(4):540-544, 2006.
57. Guarneri V, Broglio KR, Kau S, Cristofanilli M, Buzdar AU, Valero V, Buchholz TA, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in patients with hormone receptor-positive breast cancer. *J Clin Oncol* 24(7):1037-1044, 2006.
58. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden. *Clin Breast Cancer* 7(6):471-479, 2007.
59. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. *Clin Cancer Res* 13(3):920-8, 2007.
60. Cabioglu N, Gong Y, Broglio K, Islam R, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M. Expression of growth factors and chemokine receptors: New insights in the biology of inflammatory breast cancer. *Ann Oncol* 18(6):1021-1029, 2007.
61. Cristofanilli M, Valero V, Buzdar U, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. *Cancer* 110(7):1436-1444, 2007.
62. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. *Cancer* 109(3):496-501, 2007.
63. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobagyi GN. Trends for inflammatory breast cancer: Is survival improving? *Oncologist* 12(8):904-912, 2007.

64. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. *Radiology* 247(1):189-196, 2008.
65. Rao R, Kuerer H, Cristofanilli M, Broglio K, Shukla S, Rao M, Krishnamurthy S. Breast cancer in the Asian Indian population of the United States: A call for screening and education. *Breast J* 14(4):402-403, 2008.
66. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M. Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system? *Cancer* 113(9):2422-2430, 2008. PMID:18785255.
67. Cristofanilli M, Krishnamurthy S, Das CM, Reuben JM, Spohn W, Noshari J, Becker F, Gascoyne PR. Dielectric cell separation of fine needle aspirates from tumor xenografts. *J Sep Sci* 31(21):3732-3739, 2008. PMID:18958846.
68. Jeruss JS, Newman LA, Ayers GD, Cristofanilli M, Broglio KR, Meric-Bernstam F, Yi M, Waljee JF, Ross MI, Hunt KK. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. *Cancer* 112(12):2646-2654, 2008.
69. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. *Breast Cancer Res Treat* 113(3):501-507, 2008.
70. Kurrihara H, Yang DJ, Cristofanilli M, Erwin WD, Yu DF, Kohanim S, Mendez R, Kim EE. Imaging and dosimetry of (99m) Tc EC annexin V: Preliminary clinical study targeting apoptosis in breast tumors. *Appl Radiat Isot* 66(9):1175-1182, 2008. PMCID: 2562036.
71. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: Clinical activity and biological correlations. *Ann Oncol* 19(10):1713-1719, 2008.
72. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetskova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. *Breast Cancer Res Treat* 109(3):417-426, 2008.
73. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. *Int J Radiat Oncol Biol Phys* 72(2):474-484, 2008.
74. Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. *J Exp Ther Oncol* 7(4):299-312, 2008.
75. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic significance of HER-2 status in women with inflammatory breast cancer. *Cancer* 112(9):1905-1911, 2008.
76. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M. Prognostic value of body mass index in locally advanced breast cancer. *Clin Cancer Res* 14(6):1718-1725, 2008.
77. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of initial clinical disease stage after achieving pathological complete response. *Oncologist* 13(1):6-15, 2008.
78. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol* 26(8):1275-1281, 2008.

79. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. *J Surg Res* 155(2):231-236, 2009.
80. Groves MD, Hess KR, Pudevalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung A, Liu TJ. Biomarkers of disease: Cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer, and melanoma. *J Neurooncol* 94(2):229-234, 2009.
81. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast cancer metastasis: Challenges and opportunities. *Cancer Res* 69(12):4951-4953, 2009. PMID:19470768.
82. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: Differential expression in metastatic disease sites with diagnostic and therapeutic implications. *Ann Oncol* 20(6):1013-1019, 2009.
83. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M. Chronic thyroiditis in patients with advanced breast carcinoma: Metabolic and morphologic changes on PET-CT. *Eur J Nucl Med Mol Imaging* 36(6):894-902, 2009.
84. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. *J Clin Oncol* 27(20):3303-3311, 2009. PMID:19451443.
85. Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, Handy B, Reuben JM, Cristofanilli M. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. *Br J Cancer* 101(11):1813-6, 2009. PMCID: 2788266.
86. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M. CXCR4 expression in early breast cancer and risk of distant recurrent. *Oncologist* 14(12):1182-1188, 2009. PMID:19939894
87. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. *Breast Cancer Res Treat* 117(1):61-68, 2009.
88. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. *Clin Cancer Res* 15(21):6639-6648, 2009. PMCID: 2783487.
89. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. *Breast J* 15(2):176-181, 2009.
90. Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambarzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: Incorporating stem cell hypotheses into clinical trials. *Int J Radiat Oncol Biol Phys* 74(5):1580-1591, 2009.
91. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez-Angulo AM, Dawood S, Resetskova E, Le-Petross HT, Yang WT. Retrospective study of 18-FDG PET/CT in the diagnosis of inflammatory breast cancer: Preliminary Data. *J Nucl Med* 50(2):231-238, 2009.
92. Mego M, De Giorgi U, Hsu L, Ueno N, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M. Circulating tumor cells in metastatic inflammatory breast cancer. *Ann Oncol* 20(11):1824-1828, 2009. PMID:19556320.

93. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. *Ann Oncol* 21(1):33-39, 2010. PMID:19602564.
94. Singh B, Irving LR, Tai K, Cristofanilli M, Lucci A Jr. Overexpression of cyclooxygenase-2 in celecoxib-resistant breast cancer cell lines. *J Surg Res* 158(2):397-398, 2010.
95. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Agliano AM, Cristofanilli M. Chemosensitivity profile assay of circulating cancer cells (CTCs): Prognostic and predictive value in epithelial tumors. *Int J Cancer*. In Press. (Epub ahead of print)
96. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center Experience. *Clin Breast Cancer* 10(1):46-51, 2010. PMID:20133258
97. Badr H, Carmack CL, Kashy DA, Cristofanilli M, Revenson TA. Dyadic coping in metastatic breast cancer. *Health Psychology* 29(2):169-180, 2010. PMC: 3138118/NIHMS: 304855
98. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M. GPR30 and estrogen receptor expression: New insights into hormone dependence of inflammatory breast cancer. *Breast Cancer Res Treat* 123(1):51-58, 2010. PMCID: 2904403.
99. Robertson FM, Simeone A-M, Lucci A, McMurray JS, Ghosh S, Cristofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. *Cancer* 116(S11):2806-2814, 2010. PMCID: 2889924 PMC: 2889924
100. Alvarez R, Booser D, Cristofanilli M, Sahin AA, Strom E, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase II trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer: long-term results from the University of Texas M.D. Anderson Cancer Center Study ID97-099. *Cancer* 116(5):1210-1217, 2010. PMID:20082452.
101. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib in combination with paclitaxel in patients with newly diagnosed inflammatory breast cancer. *J Clin Oncol* 28(20):3248-3255, 2010. PMID:20530274
102. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill P. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. *Clin Cancer Res* 16(6):1904-1914, 2010. PMID:20215537
103. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. *Mol Cancer* 9:180, 2010. PMID: 20615238 PMCID: 2915978.
104. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. *Int J Radiat Oncol Biol Phys* 76(3):889-895, 2010. PMCID: 2892870.
105. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG-PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. *J Nucl Med* 51(8):1213-1218, 2010. PMID:20660382.
106. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and biomarkers: Implications for personalized targeted treatments for metastatic breast cancer. *Breast J.* 16(3):327-330, 2010. PMID:20408820.

107. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. *Ann Oncol* 21(12):2348-2355, 2010. PMID:20439340
108. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Trastuzumab in primary inflammatory breast cancer (IBC): High pathological response rates and improved outcome. *Breast J.* 2010 Jul 6 (Epub ahead of print) PMC: 3097300/NIHMS: 269640
109. Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, Saltarelli R, Chiapparino E, Spremberg F, Cristofanilli M, Frati L, Agliano AM, Gazzaniga P. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. *Ann Oncol* 22(1):86-92, 2011. PMID: 20603432.
110. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. *Cancer* 116(14):3330-3337, 2010. PMID:20564098.
111. Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, Cristofanilli M, Lucci A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. *Clin Exp Metastasis* 27(4):233-240, 2010. PMID:20229045
112. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. *Ann Oncol* 22(3):515-523, 2011. PMC: 3105293
113. Bianchini G, Qi Y, Alvarez R, Iwamoto T, Coutant C, Nuhad I, Valero V, Cristofanilli M, Green M, Laszlo R, Hatzis C, Hortobagyi G, Fabrice A, Gianni L, Fraser S, Pusztai, L. Molecular anatomy of breast cancer stroma and its prognostic value in ER-positive and -negative cancers. *J Clin Oncol* 28(28):4316-4323, 2010. PMID:20805453
114. Robertson FM, Osagawara M, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M, Barsky SH. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. *J Biomol Screen* 15(7):820-829, 2010. PMID:20639504
115. Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS, Cristofanilli M. Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. *Cancer* 116(11 Suppl):2760-2767, 2010. PMID:20503408/NIHMS189768
116. Robertson RM, Bondy M, Yang W, Yamauchi H, Wiggin S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno N, Cristofanilli M. Inflammatory breast cancer: The disease, the biology, the treatment. *CA Cancer J Clin* 60(6):351-375, 2010. Review.
117. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xy W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. *PLoS Onc* 5(8):e12180, 2010. PMC: 2922340
118. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. *Int J Cancer.* 2011 Mar 8. doi: 10.1002/ijc.26037. Epub ahead of print. PMC: 3169728/NIHMS: 283912
119. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. *Int J Cancer* 129(2):417-423, 2011. PMID:20857493
120. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and non-

inflammatory locally advanced breast cancer appear early: A large population based study. *Cancer* 117(9):1819-1826, 2011. PMID:21117228

121. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods for detection of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. *Int J Cancer*. 2011 Apr 5. doi: 10.1002/ijc.26111. Epub ahead of print. PMID:21469140

122. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International Expert Panel on Inflammatory Breast Cancer: consensus statement for standardized diagnosis and treatment. *Ann Oncol* 22(3):515-523, 2011. e-Pub 7/2010. PMC: 3105293.

123. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson FM, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. *Breast Cancer Res Treat*. 125(3):785-795, 2011. PMID:21153052

124. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24^{lo} cancer stem cell phenotype. *Eur J Cancer* 47(10):1527-1536, 2011. PMC: 3116032/NIHMS: 268938

125. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. *Cancer* 117(24):5476-5484, 2011. PMID:21713757.

126. De Giorgi U, Cohen EN, Gao H, Mego M, Lee BN, Lodhi A, Cristofanilli M, Lucci A, Reuben JM. Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. *Cancer Biol Ther* 11(9):812-815, 2011. PMC: 3230296

127. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. *Cancer* 117(9):1819-1826, 2011. PMID:21509759.

128. Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. *Breast Cancer Res Treat* 129(2):451-458, 2011.

129. Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer. A case series. *Int J Clin Oncol* 16(5):596-600, 2011. PMID:21210173

130. Saldova R, Reuben JM, Abd Hamid UM, Rudd PM, Cristofanilli M. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. *Ann Oncol* 22(5):1113-1119, 2011. PMID:21127012

131. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. *Ann Oncol*. 2012;23(4):870-5. doi: 10.1093/annonc/mdr319. PMID: 21765048

132. Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. *Int J Clin Oncol*. 2012 Feb;17(1):55-62. doi: 10.1007/s10147-011-0253
133. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. *Int J Clin Oncol*. 2012;17(2):96-104. doi: 10.1007/s10147-011-0260-0.
134. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. *Breast Cancer Res* 13(3):R67, 2011. PMC: 3218956
135. Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, Reed BJ, Yang WT. MRI features of inflammatory breast cancer. *AJR Am J Roentgenol* 197(4):W769-776, 2011. PMID:21940550
136. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. *Ann Oncol*. 2012 May;23(5):1144-50. doi: 10.1093/annonc/mdr434.
137. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, moore J, Rivera E, Hortobagyi GN, Tran HT. A Phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. *Cancer*. 2012 May 1;118(9):2378-84. doi: 10.1002/cncr.26571.
138. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. *Oncologist*. 2011;16(12):1675-83. doi: 10.1634/theoncologist.2011-0196.
139. Liu, H., Luo, A.Z., Mu, Z., Chu, K., Ye, Z., Alpaugh, R.K., Circo, R., Wulfkuhle, J., Fernandez, S. Boley, K.M., Jin, J., Wright, M.C., Barsky, S.H., Petricoin, E.F., Cristofanilli, M. and Robertson, F.M. Mapping the Angiogenic Pathways in Inflammatory Breast Cancer. 2011. *J. Oncol. Special Issue "Tumor Angiogenesis*. In press.
140. Robertson, F.M., Chu, K., Ye, Z., Wright, M.C., Freiter, E.M., Luo, A.Z., Jin, J., Barsky, S.H., Cristofanilli, M. and Krishnamurthy, K. Secretory Leukocyte Peptidase Inhibitor as a Biomarker and Therapeutic Target of Tumor Emboli in Inflammatory Breast Cancer. *Pathol. Res. Intl, Special Issue "Progress in Diagnosis of Breast Cancer"*, 2011.
141. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. *Breast Cancer Res*. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907.
142. Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. *Breast Cancer Res Treat*. 2012 May 1. *Breast Cancer Res Treat*. 2012 Jul;134(2):495-510. doi: 10.1007/s10549-012-2075-8. Epub 2012 May 1.

143. Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. *Br J Cancer*. 2012 Oct 9;107(8):1286-94. doi: 10.1038/bjc.2012.388. Epub 2012 Sep 6.
144. Giordano A, Cristofanilli M. CTCs in Metastatic Breast Cancer, *Recent Results Cancer Res*. 2012;195:193-201.
145. Cristofanilli M. Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. *Journal of Oncology*, 12 (2012), Article ID 703858, doi:10.1155/2012/703858
146. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. *Clin Breast Cancer*. 2012 May 14. [Epub ahead of print] PMID: 22591634
147. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Larey LA, Cristofanilli M, Denkert C, Eiermann w, Gnant M, Harris JR, Kam T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. *Ann Surg Oncol* 2011 Dec 23. Epub ahead of print. PMID:22193884
148. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. *J Cancer*. 2012;3:369-80. doi: 10.7150/jca.5111. Epub 2012 Sep 8.
149. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development of circulating tumor cell technology for clinical use. *J Transl Med*. 2012 Jul 2;10:138. doi: 10.1186/1479-5876-10-138.
150. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. *Mol Cancer Ther*. 2012 Nov;11(11):2526-34. doi: 10.1158/1535-7163.MCT-12-0460. Epub 2012 Sep 12.
151. Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. *Breast Cancer Res Treat*. 2012 Dec 13.
152. Liu S, Im H, Bairoch A, Cristofanilli M, Chen R, Deutsch EW, Dalton S, Fenyo D, Fanayan S, Gates C, Gaudet P, Hincapie M, Hanash S, Kim H, Jeong SK, Lundberg E, Mias G, Menon R, Mu Z, Nice E, Paik YK, Uhlen M, Wells L, Wu SL, Yan F, Zhang F, Zhang Y, Snyder M, Omenn GS, Beavis RC, Hancock WS. A Chromosome-centric Human Proteome Project (C-HPP) to Characterize the Sets of Proteins Encoded in Chromosome 17. *J Proteome Res*. 2013 Jan 4;12(1):45-57. doi: 10.1021/pr300985j. Epub 2012 Dec 21.

153. Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga JY, Cristofanilli M, Bidard FC. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. *Clin Cancer Res*. 2013 Jan 22.
154. Robertson FM, Chu K, Fernandez S, Mu Z, Zhang X, Liu H, Boley KM, Alpaugh RK, Ye Z, Wright MC, Luo A, Moraes R, Wu H, Zook M, Barsky SH and Cristofanilli M. Genomic profiling of pre-clinical models of inflammatory breast cancer identifies a signature of mesenchymal-epithelial plasticity and suppression of TGF beta signaling. *J Clin Exp Pathol* 2(5), 2012.
155. Van Laere S, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Iwamoto T, Van Dam P, Woodward WA, Cristofanilli M, Birnbaum D, Viens P, Dirix L, Reuben JM, Bertucci F. An integrated analysis of three distinct IBC/nIBC Affymetrix gene expression data sets: uncovering the molecular secrets of IBC-biology. *Clin Cancer Res*. Published OnlineFirst February 8, 2013; doi: 10.1158/1078-0432.CCR-12-2549.
156. Jiang ZF, Cristofanilli M, Shao ZM, Tong ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, Zeng L, Zhang M. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. *Ann Oncol*. 2013 Jul 14.
157. Cristofanilli M, Fortina P. Circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med*. 2013 Jul 4;369(1):93.
158. Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M. Inflammatory breast cancer (IBC): clues for targeted therapies. *Breast Cancer Res Treat*. 2013 Jul;140(1):23-33. doi: 10.1007/s10549-013-2600-4.
159. Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. *Ann Oncol*. 2013 Jun 24.
160. Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? *J Cancer Res Clin Oncol*. 2013 Aug;139(8):1411-6. doi: 10.1007/s00432-013-1450-0.
161. Zhang EY, Cristofanilli M, Robertson F, Reuben JM, Mu Z, Beavis RC, Im H, Snyder M, Hofree M, Ideker T, Omenn GS, Fanayan S, Jeong SK, Paik YK, Zhang AF, Wu SL, Hancock WS. Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer. *J Proteome Res*. 2013 Jun 7;12(6):2805-17. doi: 10.1021/pr4001527.
162. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. *Am J Clin Oncol*. 2013 May 2.
163. Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa S, Cristofanilli M, Vermeulen P, Dirix L, Viens P, van Laere S, Bertucci F, Reuben JM, Ueno NT. Genomic and expression analysis of microdissected inflammatory breast cancer. *Breast Cancer Res Treat*. 2013 Apr;138(3):761-72. doi: 10.1007/s10549-013-2501-6.

164. Siraj M., Alpaugh R.K., Buell JK, Stephens PJ, Qin J M, Wu H., Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor response of an ERBB2 Amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TIKI Erlotinib. *Clinical Breast Cancer* Oct 2013.
165. Robertson FM, Petricoin EF, Van Laere SJ Bertucci F., Chu K, Fernandez SV, Mu Z., Alpaugh K, Pei J, Circo R., Wulfkuhle J, Ye Z., Boley KM., Liu H., Moraes R., Zhang X, DeMaria R., Barsky S, Sun G., Cristofanilli M. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. *SpringerPlus* 2013, 2:497.
166. Jeselsohn Rinath; Yelensky R., Guchwalter G., Frampton G.M., Meric-Bernstam F., Gonzalez-Angulo A.M., Ferrer-Lozano J., Perez-Fidalgo A., Cristofanilli M., et al. Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor positive breast cancer. *Clinical Cancer Research* 12.13.2013. online.
167. Cristofanilli M. Update on Novel Drug Targets in Metastatic Breast Cancer. *Contemporary Oncology*. 6. No2. 6-11. 04.14.
168. Cristofanilli M. Circulating tumour Cells: Telling the Truth about Metastasis. *The Lancet Oncology*. Vol 15. 365-366. 4.14.
169. Cristofanilli M. Circulating tumor cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. *Thrombosis and Haemostasis*. Manuscript TH-14-07-0597.R1 PrePrint Online . February 2015.
170. Mego M., Giordano A., DeGiorgi U., Hiroko M., Limin H., Giulian M., Fouad MTamer, Dawood S., Ueno N.T., Valero V., Andreopoulou E., Alvarez R.H., Woodward W.A, Hortobagyi G.N., Cristofanilli M., Reuben J.M. Circulating tumor cells in newly diagnosed breast cancer. *Breast Cancer Research* 2015, 17:2.
- 171.** Lai Y, Palazzo JP, Cristofanilli M, Hyslop T, Civan J, Avery T, Myers RE, Li B, Ye Z, Xing J, Yang H. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. *Breast Cancer Res Treat*. 2014 Nov;148(1):175-85. PubMed PMID: 25261294.
172. Turner NC, Jungsil R, Andre F., Loi S., Verma S., Hiroji I., Harbeck N., Loibi S., Bartlett CH., Ke Z., Giorgetti C., Randolph S., KoehlerM., **Cristofanilli M.** Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. *N Engl J Med*. 2015 16;373(3):209-19. doi: 10.1056/NEJMoa1505270.
173. **Cristofanilli M**, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;17(4):425-39. doi: 10.1016/S1470-2045(15)00613-0.
174. Amoroso V, Generali D, Buchholz T, **Cristofanilli M**, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). *J Natl Cancer Inst Monogr*. 2015 ;2015(51):90-6. doi:

175. Van Poznak C, Somerfield MR, Bast RC, **Cristofanilli M**, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2015 Aug 20;33(24):2695-704. doi: 10.1200/JCO.2015.61.1459.
176. Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb B, Giordano A, Tin S, Wu Q, Garza RJ, **Cristofanilli M**, Mani SA, Croix DA, Ueno NT, Woodward WA, Luthra R, Krishnamurthy S, Reuben JM. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. *PLoS One*. 2015 Jul 24;10(7):e0132710. doi: 10.1371/journal.pone.0132710.
177. Yao K, Goldschmidt R, Turk M, Wesseling J, Stork-Sloots L, de Snoo F, **Cristofanilli M**. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. *Breast Cancer Res Treat*. 2015 Nov;154(1):81-8. doi: 10.1007/s10549-015-3587-9.
178. Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, **Cristofanilli M**. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. *Breast Cancer Res Treat*. 2015 Nov;154(1):155-62. doi: 10.1007/s10549-015-3592-z.
- 179.** Hamm CA, Moran D, Rao K, Trusk PB, Pry K, Sausen M, Jones S, Velculescu VE, **Cristofanilli M**, Bacus S. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. *Mol Cancer Ther*. 2016 Jul;15(7):1746-56
180. Salem I, Alsalahi M, Chervoneva I, Aburto LD, Addya S, Ott GR, Ruggeri BA, **Cristofanilli M**, Fernandez SV. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. *Breast Cancer Res*. 2016 Mar 24;18(1):37. doi: 10.1186/s13058-016-0694-4.
181. Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, **Cristofanilli M**. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. *Breast Cancer Res Treat*. 2015 Dec;154(3):563-71. doi: 10.1007/s10549-015-3636-4.
182. Wurth R, Tarn K, Jernigan D, Fernandez SV, **Cristofanilli M**, Fatatis A, Meucci O. A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process. *Transl Oncol*. 2015 Oct;8(5):358-67. doi: 10.1016/j.tranon.2015.07.002.
183. Ogony J, Choi HJ, Lui A, **Cristofanilli M**, Lewis-Wambi J. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. *Breast Cancer Res*. 2016 Feb 20;18(1):25. doi: 10.1186/s13058-016-0683-7.
184. Harbeck N, Iyer S, Turner N, **Cristofanilli M**, Ro J, André F, Loi S, Verma S, Iwata H, Bhattacharyya H, Puyana Theall K, Bartlett CH, Loibl S. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. *Ann Oncol*. 2016 Jun;27(6):1047-54. doi: 10.1093/annonc/mdw139.
185. Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, **Cristofanilli M**, Tang CM, Alpaugh RK. Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. *Breast Cancer Res*. 2016 May 4;18(1):44. doi: 10.1186/s13058-016-0706-4.
186. Adams DL, Adams DK, Alpaugh RK, **Cristofanilli M**, Martin SS, Chumsri S, Tang CM, Marks JR. Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. *Cancer Epidemiol Biomarkers Prev*. 2016 Jul;25(7):1037-42. doi: 10.1158/1055-9965.EPI-15-1221

187. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, **Cristofanilli M**, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. *J Clin Oncol*. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061.
188. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, **Cristofanilli M**, Reuben JM. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. *J Cancer*. 2016 Jun 3;7(9):1095-104. doi: 10.7150/jca.13098.
189. Joyce BT, Gao T, Zheng Y, Liu L, Zhang W, Dai Q, Shrubsole MJ, Hibler EA, **Cristofanilli M**, Zhang H, Yang H, Vokonas P, Cantone L, Schwartz J, Baccarelli A, Hou L. Prospective changes in global DNA methylation and cancer incidence and mortality. *Br J Cancer*. 2016 Aug 9;115(4):465-72. doi: 10.1038/bjc.2016.205.
190. Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, **Cristofanilli M**, Zhang K, Thiele A, Turner NC, Rugo HS. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). *Oncologist*. 2016 Oct;21(10):1165-1175.
191. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, **Cristofanilli M**, Reuben JM. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. *Oncotarget*. 2016 Jun 25. doi: 10.18632/oncotarget.10290.
192. Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, **Cristofanilli M**, Giles F, O'Halloran T, Cryns VL, Mazar AP. GSK-3 inhibition overcomes chemoresistance in human breast cancer. *Cancer Lett*. 2016 Oct 1;380(2):384-92. doi: 10.1016/j.canlet.2016.07.006.
193. Zhang S, Li L, Wang T, Bian L, Hu H, Xu C, Liu B, Liu Y, Cristofanilli M, Jiang Z. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. *BMC Cancer*. 2016 Jul 25;16:526. doi: 10.1186/s12885-016-2578-5.
194. Toss A, Palazzo J, Berger A, Guiles F, Sendecki JA, Simone N, Anne R, Avery T, Jaslow R, Lazar M, Tsangaris T, **Cristofanilli M**. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. *Breast*. 2016 Oct;29:223-30. doi: 10.1016/j.breast.2016.07.023.
195. Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, **Cristofanilli M**, Plataniias LC, Giles FJ. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. *Oncotarget*. 2016 Oct 4;7(40):65364-65373. doi: 10.18632/oncotarget.11692.
196. Johnston S, Basik M, Hegg R, Lausontornsiri W, Grzeda L, Clemons M, Dreosti L, Mann H, Stuart M, **Cristofanilli M**. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. *Breast Cancer Res Treat*. 2016 Nov;160(1):91-99. Epub 2016 Sep 21.
197. Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, Palazzo JP, Sun C, Abu-Khalaf M, Myers RE, Zhu Z, Ba Y, Li B, Hou L, **Cristofanilli M**, Yang H. Longitudinally collected CTCs and CTC-

- clusters and clinical outcomes of metastatic breast cancer. *Breast Cancer Res Treat.* 2017 Jan;161(1):83-94. doi: 10.1007/s10549-016-4026-2.
198. Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WH, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, **Cristofanilli M**, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. *Proc Natl Acad Sci U S A.* 2016 Oct 24. pii: 201615288.
199. Lin J, Patel SA, Sama AR, Hoffman-Censits JH, Kennedy B, Kilpatrick D, Ye Z, Yang H, Mu Z, Leiby B, Lewis N, **Cristofanilli M**, Kelly WK. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. *Oncologist.* 2016 Nov;21(11):1296-1297e. doi: 10.1634/theoncologist.2016-0297.
200. Bingham C, Fernandez SV, Fittipaldi P, Dempsey PW, Ruth KJ, **Cristofanilli M**, Katherine Alpaugh R. Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. *Breast Cancer Res Treat.* 2017 Jun;163(2):219-230. doi: 10.1007/s10549-017-4176
201. Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron SA, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle JD, Gambaro G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, **Cristofanilli M**, Leyland Jones B, Liotta L, O'Shaughnessy JA, Carpten JD, Petricoin EF. Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer. *Clin Cancer Res.* 2017 Apr 26. pii: clincanres.2656.2016. doi: 10.1158/1078-0432.CCR-16-2656.
202. Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanius LC, Gradishar W, Giles FJ, **Cristofanilli M**. Concordance of genomic alterations by next-generation sequencing (NGS) in tumor tissue versus circulating tumor DNA in breast cancer. *Mol Cancer Ther.* 2017 Apr 26. pii: molcanther.0061.2017. doi: 10.1158/1535-7163.MCT-17-0061.
203. Schott AF, Goldstein L, **Cristofanilli M**, Ruffini PA, McCanna S, Reuben JM, Perez R, Kato G, Wicha MS. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC). *Clin Cancer Res.* 2017 May 24. pii: clincanres.2748.2016. doi:
204. Paolillo C, Mu Z, Rossi G, Schiewer MJ, Nguyen T, Austin L, Capoluongo E, Knudsen K, **Cristofanilli M**, Fortina P. Detection of Activating Estrogen Receptor Gene (*ESR1*) Mutations in Single Circulating Tumor Cells. *Clin Cancer Res.* 2017 Oct 15;23(20):6086-6093.
205. Mu Z, Wang C, Ye Z, Rossi G, Sun C, Li L, Zhu Z, Yang H, **Cristofanilli M**. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. *Breast Cancer Res Treat.* 2017 Jul 7. doi: 10.1007/s10549-017-4372-8.
206. Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, **Cristofanilli M**, Rosellini P, Generali D. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. *Eur J Cancer.* 2017 Nov;86:257-265. doi: 10.1016/j.ejca.2017.09.018.
207. Rossi G, Mu Z, Rademaker A, Austin L, Strickland KS, Lima Barros Costa R, Nagy R, Zagonel V, Taxter TJ, Behdad A, Wehbe FH, Platanius LC, Gradishar W, **Cristofanilli M**. Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer. *Clin Cancer Res.* 2017 Nov 27. pii: clincanres.2092.2017. doi: 10.1158/1078-0432.CCR-17-2092.

208. Cruz M, Reinert T, Cristofanilli M. Emerging innovative therapeutic approaches leveraging cyclin-dependent kinase inhibitors to treat advanced breast cancer. *Clin Pharmacol Ther.* 2017 Dec 11. doi: 10.1002/cpt.965.
209. Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V, Cristofanilli M, Giles F. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? *Oncotarget.* 2017 Aug 1;8(59):100863-100898. doi: 10.18632/oncotarget.19809.
210. Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor- β Insensitive Genetically Targeted CD8⁺ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. *Eur Urol.* 2017 Dec 21. pii: S0302-2838(17)31040-0. doi: 10.1016/j.eururo.2017.12.008.
211. Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, **Cristofanilli M**, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases. *Ann Oncol.* 2018 Jan 11. doi: 10.1093/annonc/mdx797. [Epub ahead of print] PMID: 29342248
212. Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, **Cristofanilli M**, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG. CCR5 governs DNA damage and breast cancer stem cell expansion. *Cancer Res.* 2018 Jan 22. pii: canres.0915.2017. doi: 10.1158/0008-5472.CAN-17-0915.
213. Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, **Cristofanilli M**, Schiff R, Trivedi MV. Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. *Cancer Res.* 2018 Feb 15;78(4):845-852. doi: 10.1158/0008-5472.CAN-17-2748.
214. O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, **Cristofanilli M**, Garcia-Murillas I, Bliss JM, Turner NC. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. *Nat Commun.* 2018 Mar 1;9(1):896. doi: 10.1038/s41467-018-03215-x.
215. Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, **Cristofanilli M**, Chae YK, Giles FJ, Abdulkadir SA. Anaplastic lymphoma kinase mutation (*ALK* F1174C) in small cell carcinoma of the prostate and molecular response to alectinib. *Clin Cancer Res.* 2018 Mar 20. pii: clincanres.0332.2018. doi: 10.1158/1078-0432.CCR-18-0332.
216. Dogan BE, Yuan Q, Bassett R, Guvenc I, Jackson EF, **Cristofanilli M**, Whitman GJ. Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. *Curr Probl Diagn Radiol.* 2018 Mar 28. pii: S0363-0188(18)30007-0. doi: 10.1067/j.cpradiol.2018.03.003. [Epub ahead of print].
217. Woodward WA, **Cristofanilli M**, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary

from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. *J Cancer*. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

218. Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, **Cristofanilli M**, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. *Hum Pathol*. 2018 Apr 21. pii: S0046-8177(18)30122-9. doi: 10.1016/j.humpath.2018.04.002.

219. Ueno NT, Espinosa Fernandez JR, **Cristofanilli M**, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. *J Cancer*. 2018 Apr 6;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.

220. Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, **Cristofanilli M**, Nakamura Y, Giles FJ. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. *Oncotarget*. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10

221. Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, **Cristofanilli M**, Gradishar WJ. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. *Breast Cancer Res Treat*. 2018 May 30. doi: 10.1007/s10549-018-4792-0.

222. Goodman CR, Seagle BL, Friedl TWP, Rack B, Lato K, Fink V, **Cristofanilli M**, Donnelly ED, Janni W, Shahabi S, Strauss JB. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. *JAMA Oncol*. 2018 May 3:e180163. doi: 10.1001/jamaoncol.2018.0163.

223. Simone BA, Palagani A, Strickland K, Ko K, Jin L, Lim MK, Dan TD, Sarich M, Monti DA, **Cristofanilli M**, Simone NL. Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model. *Cell Cycle*. 2018;17(13):1536-1544. doi: 10.1080/15384101.2018.1471314.

224. Rolfo C, Raez L, **Cristofanilli M**. Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. *JAMA Oncol*. 2018 Jul 19. doi: 10.1001/jamaoncol.2018.2320.

225. Diéras V, Rugo HS, Schnell P, Gelmon K, **Cristofanilli M**, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. *J Natl Cancer Inst*. 2018 Jul 18. doi: 10.1093/jnci/djy109.

226. Kang HJ, Song HY, Ahmed MA, Guo Y, Zhang M, Chen C, **Cristofanilli M**, Horiuchi D, Vassilopoulos A. NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. *Free Radic Biol Med*. 2018 Oct;126:358-371. doi: 10.1016/j.freeradbiomed.2018.08.009.

227. Qian C, Worrede-Mahdi A, Shen F, DiNatale A, Kaur R, Zhang Q, **Cristofanilli M**, Meucci O, Fatatis A. Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy. *Mol Cancer Res*. 2018 Aug 16. doi: 10.1158/1541-7786.MCR-18-0302.
228. Toss A, Piacentini F, Cortesi L, Artuso L, Bernardis I, Parenti S, Tenedini E, Ficarra G, Maiorana A, Iannone A, Omarini C, Moschetti L, **Cristofanilli M**, Federico M, Tagliafico E. Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. *Oncotarget*. 2018 Aug 3;9(60):31606-31619. doi: 10.18632/oncotarget.25810.
229. O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, Andre F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. *Cancer Discov*. 2018 Sep 11. pii: CD-18-0264. doi: 10.1158/2159-8290.CD-18-0264.
230. Trosman JR, Weldon CB, Gradishar WJ, Benson AB 3rd, **Cristofanilli M**, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. *Value Health*. 2018 Sep;21(9):1062-1068. doi: 10.1016/j.jval.2018.06.011.
231. **Cristofanilli M**, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. *Eur J Cancer*. 2018 Oct 8;104:21-31. doi: 10.1016/j.ejca.2018.08.011.
232. Croessmann S, Formisano L, Kinch L, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, **Cristofanilli M**, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin N, Arteaga CL. Combined blockade of activating *ERBB2* mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer. *Clin Cancer Res*. 2018 Oct 12. pii: clincanres.1544.2018. doi: 10.1158/1078-0432.CCR-18-1544.
233. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, **Cristofanilli M**, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. *J Clin Oncol*. 2018 Oct 19;JCO1800328. doi: 10.1200/JCO.18.00328.
234. Turner NC, Dennis J, Slamon, DJ, Ro J, Bondarenko I, Im S-A, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Theall KP, Huang X, Giorgetti C, Bartlett CH, and **Cristofanilli M**. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. *N Engl J Med*. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527.
235. Liu X, Taftaf R, Kawaguchi M, Chang YF, Chen W, Entenberg D, Zhang Y, Gerratana L, Huang S, Patel DB, Tsui E, Adorno-Cruz V, Chirieleison SM, Cao Y, Harney AS, Patel S, Patsialou A, Shen Y, Avril S, Gilmore HL, Lathia JD, Abbott DW, **Cristofanilli M**, Condeelis JS, Liu H. Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. *Cancer Discov*. 2018 Oct 25. doi: 10.1158/2159-8290.CD-18-0065
236. Ye Z, Wang C, Wan S, Mu Z, Zhang Z, Abu-Khalaf MM, Fellin FM, Silver DP, Neupane M, Jaslow RJ, Bhattacharya S, Tsangaris TN, Chervoneva I, Berger A, Austin L, Palazzo JP, Myers RE, Pancholy N, Toorkey D, Yao K, Krall M, Li X, Chen X, Fu X, Xing J, Hou L, Wei Q, Li B, **Cristofanilli M**, Yang

- H. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. *Eur J Cancer*. 2019 Jan;106:133-143. doi: 10.1016/j.ejca.2018.10.012.
237. Turner NC, Huang X, **Cristofanilli M**. Palbociclib and Fulvestrant in Breast Cancer. Reply. *N Engl J Med*. 2019 Feb 21;380(8):797. doi: 10.1056/NEJMc1816595.
238. Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, **Cristofanilli M**. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. *J Clin Oncol*. 2019 Feb 26;JCO1800925. doi: 10.1200/JCO.18.00925.
239. Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, **Cristofanilli M**, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. *Nat Commun*. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2.
240. Mego M, Karaba M, Minarik G, Benca J, Silvia J, Sedlackova T, Manasova D, Kalavska K, Pindak D, **Cristofanilli M**, Reuben JM, Mardiak J. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer. *Anticancer Res*. 2019 Apr;39(4):1829-1837. doi: 10.21873/anticancer.13290.
241. Yanez B, Bouchard LC, Cella D, Sosman JA, Kircher SM, Mohindra NA, **Cristofanilli M**, Penedo FJ. Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms. *Cancer*. 2019 Apr 29. doi: 10.1002/ncr.32030.
242. Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, **Cristofanilli M**, Ning Z, Lu X. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0.
243. Cohen EN, Fouad TM, Lee BN, Arun BK, Liu D, Tin S, Gutierrez Barrera AM, Miura T, Kiyokawa I, Yamashita J, Alvarez RH, Valero V, Woodward WA, Shen Y, Ueno NT, **Cristofanilli M**, Reuben JM. Elevated serum levels of sialyl Lewis X (sLe^x) and inflammatory mediators in patients with breast cancer. *Breast Cancer Res Treat*. 2019 May 3. doi: 10.1007/s10549-019-05258-0.
244. Zhou Z, Feng Z, Hu D, Yang P, Gur M, Bahar I, **Cristofanilli M**, Gradishar WJ, Xie XQ, Wan Y. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy. *EBioMedicine*. 2019 May 14. pii: S2352-3964(19)30312-3. doi: 10.1016/j.ebiom.2019.05.011.
245. Beck TN, Bumber YA, Aggarwal C, Pei J, Thrash-Bingham C, Fittipaldi P, Vlasenkova R, Rao C, Borghaei H, **Cristofanilli M**, Mehra R, Serebriiskii I, Alpaugh RK. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. *BMC Cancer*. 2019 Jun 19;19(1):603. doi: 10.1186/s12885-019-5795-x.
246. Di Sante G, Pagé J, Jiao X, Nawab O, **Cristofanilli M**, Skordalakes E, Pestell RG. Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immunoncology. *Expert Rev Anticancer Ther*. 2019 Jul;19(7):569-587. doi: 10.1080/14737140.2019.1615889.

247. Gerratana L, Davis AA, Shah AN, Lin C, Corvaja C, **Cristofanilli M**. Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. *Curr Treat Options Oncol*. 2019 Jun 29;20(8):68. doi: 10.1007/s11864-019-0667-9.
248. Devi GR, Hough H, Barrett N, **Cristofanilli M**, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, Hollister BA, Palmer G, Force J, Westbrook K, Fayanju O, Suneja G, Dent SF, Hwang ES, Patierno SR, Marcom PK. Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. *J Cancer*. 2019 Jun 4;10(15):3344-3351. doi: 10.7150/jca.31176. eCollection 2019.
249. Gelmon KA, **Cristofanilli M**, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleekman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. *Breast J*. 2019 Aug 25. doi: 10.1111/tbj.13516.
250. De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, Alvarez RH, Ueno NT, **Cristofanilli M**, Reuben JM. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. *Ther Adv Med Oncol*. 2019 Aug 14;11:1758835919866065. doi: 10.1177/1758835919866065.
251. Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, **Cristofanilli M**, Giordano A, Puglisi F, Pistilli B, Prat A, Del Mastro L, Venturini S, Generali D. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. *Lancet Oncol*. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6.
252. O'Leary B, Hrebien S, Beaney M, Fribbens C, Garcia-Murillas I, Jiang J, Li Y, Huang Bartlett C, André F, Loibl S, Loi S, **Cristofanilli M**, Turner NC. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. *Clin Chem*. 2019 Sep 24. pii: clinchem.2019.305805. doi: 10.1373/clinchem.2019.305805.
253. Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, **Cristofanilli M**, Gradishar WJ, Lesniak MS. Current state of clinical trials in breast cancer brain metastases. *Neurooncol Pract*. 2019 Sep;6(5):392-401. doi: 10.1093/nop/npz003
254. Reduzzi C, Vismara M, Gerratana L, Silvestri M, De Braud F, Raspagliesi F, Verzoni E, Di Cosimo S, Locati LD, **Cristofanilli M**, Daidone MG, Cappelletti V. The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. *Semin Cancer Biol*. 2019 Oct 15. pii: S1044-579X(19)30170-1. doi: 10.1016/j.semcancer.2019.10.008.
255. Chi JJ, Li H, Zhou Z, Izquierdo-Ferrer J, Xue Y, Wavelet CM, Schiltz GE, Zhang B, **Cristofanilli M**, Lu X, Bahar I, Wan Y. [A novel strategy to block mitotic progression for targeted therapy](#). *EBioMedicine*. 2019;49:40-54. doi: 10.1016/j.ebiom.2019.10.013.
256. Davis AA, Zhang Q, Gerratana L, Shah AN, Zhan Y, Qiang W, Finkelman BS, Flaum L, Behdad A, Gradishar WJ, Plataniias LC, **Cristofanilli M**. [Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells \(CTCs\) and CTC clusters in metastatic breast cancer](#). *Breast Cancer Res*. 2019;21(1):137. doi: 10.1186/s13058-019-1229-6.
257. Bertucci F, Rypens C, Finetti P, Guille A, Adelaïde J, Monneur A, Carbuccion N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, **Cristofanilli M**, Chaffanet

M, Birnbaum D, Van Laere S. [NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers](#). *Mol Oncol*. 2019. doi: 10.1002/1878-0261.12621.

258. Gerratana L, Zhang Q, Shah AN, Davis AA, Zhang Y, Wehbe F, Qiang W, Flaum L, Finkelman BS, Gradishar WJ, Platanius LC, Behdad A, **Cristofanilli M**. [Performance of a novel Next Generation Sequencing circulating tumor DNA \(ctDNA\) platform for the evaluation of samples from patients with metastatic breast cancer \(MBC\)](#). *Crit Rev Oncol Hematol*. 2019;145:102856. doi: 10.1016/j.critrevonc.2019.102856.

Invited Articles

1. Cristofanilli M, Hortobagyi GN. Bisphosphonates in the management of breast cancer. *Cancer Control* 6(3):241-246, 1999.
2. Cristofanilli, M, Hortobagyi GN. Gene therapy for advanced breast and ovarian cancer. *J Women's Cancer* 1(2):101-110, 2000.
3. Cristofanilli M, Hortobagyi GN. New horizons in treating metastatic disease. *Clin Breast Cancer* 1(4):276-87, 2001.
4. Cristofanilli, M, Hortobagyi GN. Prevention strategies for breast cancer. *Ref Gynecol Obstet* 8:453-69, 2001.
5. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: Novel clinical approaches. *Nat Rev Drug Discov* 1:415-26, 2002.
6. Esteva FJ, Sahin A, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. *Semin Radiat Oncol* 12:319-328, 2002.
7. Cristofanilli M Hortobagyi GN. Molecular targets in breast cancer: Current status and future directions. *Endocr Relat Cancer* 9:249-66, 2002.
8. Cristofanilli M, Hortobagyi GN. Updated in the management of inflammatory breast cancer. *Oncologist* 8:141-148, 2003.
9. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *Semin Oncol* 33:S9-14, 2006.
10. Yang CH, Cristofanilli M. The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. *Future Oncol* 2(2):247-55, 2006.
11. Dawood S, Cristofanilli M. Endocrine resistance in breast cancer: What really matters? *Ann Oncol* 18(8):1289-1291, 2007.
12. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. *Cancer* 109(12):2392-404, 2007.

13. Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. *Semin Oncol* 34(Suppl 3):S10-S16, 2007.
14. Yang CH, Cristofanilli M. Systemic treatments for inflammatory breast cancer. *Breast Dis* 22:55-65, 2007.
15. Dawood S, Cristofanilli M. What progress have we made in managing inflammatory breast cancer? *Oncology* 21(6):673-9; discussion 679-80, 686-7. Review, 2007.
16. Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. *Semin Oncol* 35(1):7-10, 2008.
17. Cristofanilli M. Inflammatory breast cancer: Defining a new entity. *Semin Oncol* 35(1):6, 2008.
18. Dawood S, Cristofanilli M. Integrating circulating tumor cell assays into the management of breast cancer. *Curr Treat Options Oncol* 8(1):89-95, 2008.
19. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. *Clin Cancer Res* 14(23):7909-7916, 2008.
20. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. *Semin Oncol* 35(1):64-71, 2008.
21. Reuben JM, Krishnamurthy S, Woodward W, Cristofanilli M. The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. *Expert Opin Med Diagn* 2(4):339-348, 2008.
22. Yamauchil H, Cristofanilli M, Nakamural S, Hortobagyi GN, Ueno N. Molecular targets for treatment of inflammatory breast cancer. *Nat Rev Clin Oncol* 6(7):387-394, 2009.
23. Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM. Nanotechnology for breast cancer therapy. *Biomed Microdevices* 11(1):49-63, 2009.
24. Cristofanilli M. The biological information obtainable from circulating tumor cells. *Breast* 118(S3):S38-S40, 2009. PMID:19914540
25. Woodward WA, Cristofanilli M. Inflammatory breast cancer. *Semin Radiat Oncol* 19(4):256-265, 2009.
26. Cristofanilli M, Braun S. Circulating tumor cells revisited. *JAMA* 303(11):1092-1093, 2010. PMID:20233831
27. Cristofanilli M. Novel targeted therapies in inflammatory breast cancer. *Cancer* 116(S11):2837-2839, 2010. PMID:20503416
28. Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS, Cristofanilli M. Suberoylanilide hydroxamic acid block self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. *Cancer* 116(S11):2760-2767, 2010.
29. Cristofanilli M, Buchholz TA. Proceedings of the first international inflammatory breast cancer conference. *Cancer* 116(S11):2729, 2010. PMID:20503400
30. Andredopoulou E, Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer. *Expert Rev Anticancer Ther* 10(2):171-177, 2010. PMID:20131993
31. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. *Ann Oncol* 22(3):515-523, 2011.
32. Mego M, Mani S, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. *Nature Rev Clin Oncol* 7(12):693-701, 2010. Review. PMID:20956980
33. Robertson FM, Cristofanilli M. A global approach to inflammatory breast cancer. *Future Oncol* 7(1):25-30, 2011. PMID:21174535

34. Yu JQ, Cristofanilli M. Circulating tumor cells and PET. *J Nucl Med* 52(10):1501-1504, 2011. PMID:21911596
35. Dushkin H, Cristofanilli M. inflammatory Breast Cancer. *J Natl Compr Canc Netw* 9(2):233-240, 2011. PMID:21310744
36. Dawood S, Cristofanilli M. Inflammatory breast cancer: what progress have we made? *Oncology (Williston Park)* 25(3):264-273, 2011. Review. PMID:21548470
37. Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. *BMC Med* 9:43, 2011 Review. PMID:21510857
38. Robertson F and Cristofanilli M: Novel therapeutic targets in IBC. *Curr Breast Cancer Rep* DOI 10.1007/s12609-012-0087-3

Editorials

1. Cristofanilli M. Development and preclinical evaluation of a bacillus calmette-guerin-MUC1-based novel breast cancer vaccine. *Breast Diseases. A Year Book Quarterly* 14(4):402, 2003.
2. Cristofanilli M. Inflammatory breast carcinoma and non-inflammatory locally advanced breast carcinoma: Distinct clinicopathologic entities? *Breast Diseases. A Year Book Quarterly* 14(4):370, 2003.
3. Cristofanilli M. Inflammatory breast carcinoma: Time to define new standards for diagnosis and treatment. *The American Journal of Oncology Review* 2:638-639, 2003.
4. Cristofanilli, M, Hortobagyi GN. Breast cancer in the highlights: Key findings from the San Antonio Breast Cancer Symposium. A U.S. Perspective. *Oncologist* 9(4):471-478, 2004.
5. Cristofanilli M. China approves first gene therapy. *Nature Biotechnology* 22(1):3-4, 2004.
6. Cristofanilli M. A multigene assay for predicting the recurrence of tamoxifen-treated, node-negative breast cancer. *Breast Diseases. A Year Book Quarterly* 16(3):219-220, 2005.
7. Cristofanilli M. The microscopic revolution in breast carcinoma. *Cancer* 1(5):877-880, 2005.
8. Cristofanilli M, Mendelsohn J. Circulating tumor cells in breast cancer: Advanced tools for tailored therapy? *PNAS* 103(46):17073-17074, 2007.
9. Dong X, Alpaugh KR, Cristofanilli M. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. *Chin J Cancer Res.* 2012; 24(4): 388–398.
10. Cristofanilli M. Inflammatory breast cancer: a new approach. *Lancet Oncol.* 2016 May;17(5):544-6. doi: 10.1016/S1470-2045(16)00064-4.
11. Cristofanilli M. Metastatic breast cancer: focus on endocrine sensitivity. *Lancet.* 2016 Dec 17;388(10063):2961-2962. doi: 10.1016/S0140-6736(16)32418-7.
12. **Cristofanilli M.** Time for a shift in molecular down staging in luminal breast cancer. *Lancet Oncol.* 2020 Jan;21(1):2-3. doi: 10.1016/S1470-2045(19)30806-X.

Other Articles

1. Pantel, K, Cristofanilli F, Hayes DF, Park JW. Researchers exploring implications of minimal residual cancer. *JNCI* 97(22):1642-1643, 2005.
2. Woodward WA, Lucci A, Cristofanilli M. A gene signature in breast cancer. *N Engl J Med* 356, 18):1887-1888, 2007.

3. De Giorgi U, Perkins GH, Cristofanilli M. Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: Does the possible triumph over the actual? *J Clin Oncol* 26(24):4044-4045, 2008.
4. Hayes DF, Cristofanilli M. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. *J Natl Cancer Inst* 101(12):894-895, 2009.
5. Dawood S, Cristofanilli M. Reply to differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population-based study. *Cancer*, Jul 15. Epub ahead of print. PMID: 21766305
6. **Cristofanilli M.** Potential of liquid biopsies in detecting cancer and establishing prognosis. A conversation. *The ASCO Post*. 9.15.2014, vol 5, Issue 15.

Abstracts (past 5 years/not updated)

1. Dawood S, Broglio K, Reuben JM, Handy B, Han X, Ginsberg C, Remus L, Sun X, Islam R, Kau SW, Fritsche H, Valero V, Ueno N, Hortobagyi GN, Massimo Cristofanilli M. Circulating Tumor Cells (CTCs) and Prognostic Stratification in Metastatic Breast Cancer (MBC): Need for a Modification of the AJCC Staging System? 2007 San Antonio Breast Cancer Symposium (#111), 2007.
2. Reuben JM, Lee B-N, Li C, Broglio KR, Valero V, Jackson S, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Genomics of circulating tumor cells in metastatic breast cancer. *J Clin Oncol* (#1002), 2007.
3. Woodward WA, Reuben JM, Gao H, Krishnamurthy S, Lucci A, Singh B, Li L, Cristofanilli M. Preliminary characterization and in vitro propagation of putative stem/progenitor cells from human inflammatory breast cancer. 2007 San Antonio Breast Cancer Symposium (#4099), 2007.
4. Woodward W, Zhang M, Gao H, Cohen E, Debeb B, Xu W, Reuben J, Krishnamurthy S, Lucci A, Ueno N, Olive M, Singh B, Robertson F, Buchholz T, Lewis M, Cristofanilli M. A novel cell line derived from an adherent subpopulation of metastatic inflammatory breast cancer cells cultured in mammosphere conditions. *SABCS*, 2008.
5. Cristofanilli M, De Giorgi U, Rohren E, Ueno NT, Miller C, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Hortobagyi GN, Macapinlac HA, Fritsche HA, Valero V. Circulating tumor cells and FDG-PET/CT: biological and functional methods for therapeutic monitoring in metastatic breast cancer. 2008 San Antonio Breast Cancer Symposium (#6052), 2008.
6. Li C, Pusztai L, Cohen EN, Symmans F, Wang B, Lee BN, Hortobagyi GN, Cristofanilli M, Reuben JM. Epstein-Barr Virus (EBV) in fine needle aspirates containing inflammatory breast cancer cells. 2008 San Antonio Breast Cancer Symposium (#3084), 2008.
7. Lucci A, Krishnamurthy S, Mosalpuria K, Bedrosian I, Meric-Bernstam F, Reuben JM, Singh B, Woodward WA, Cristofanilli M. Global evaluation of minimal residual disease in primary breast cancer patients. 2008 ASCO Annual Meeting (#1020), 2008.
8. Cohen EN, Jimenez C, Gao H, Lee BN, Li C, Krishnamurthy S, Woodward WA, Andreopoulou E, Bethancourt DL, Hortobagyi GN, Cristofanilli M, Reuben JM. Immune cells from pleural fluids of patients with inflammatory breast cancer are immunocompetent. 2008 San Antonio Breast Cancer Symposium (#5044), 2008.
9. Lee BN, Li C, Lucci A, Cohen EN, Gao H, Krishnamurthy S, Ueno NT, Hortobagyi GN, Cristofanilli M, Woodward WA, Reuben JM. Notch-1 expression is not related to the percentage of CD326+ cells in bone marrow aspirates of patients with primary breast cancer. 2008 San Antonio Breast Cancer Symposium (#4030), 2008.
10. Hall Cs, Debeb BG, Xu W, Ueno NT, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward WA. Novel inflammatory breast cancer cell line, MDA-IBC-1 expresses and secretes WISP3, a putative tumor suppressor in inflammatory breast cancer. 2008 San Antonio Breast Cancer Symposium (#1051), 2008.
11. Debeb, BG, Hall CS, Xu W, Ueno NT, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward WA. Populations of cells exhibiting epithelial-mesenchymal transition (EMT) or stem cell characteristics can be propagated from a single inflammatory breast cancer (IBC) cell line based on culture conditions. 2008 San Antonio Breast Cancer Symposium, 2008.

12. Gao H, Lucci A, Cohen EN, Lee BN, Li C, Krishnamurthy S, Ueno NT, Andreopoulou E, De Giorgi U, Hortobagyi GN, Cristofanilli M, Woodward WA, Reuben JM. Primary tumor size is associated with ALDH⁺ breast cancer initiating stem cells in bone marrow aspirates of primary breast cancer patients. 2008 San Antonio Breast Cancer Symposium (#4031), 2008.
13. Robertson FM, Simeone A-M, Lucci A, Woodward W, Reuben J, Ueno NT, Cristofanilli M. Role of the prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer. 2008 San Antonio Breast Cancer Symposium (#2127), 2008.
14. Ueno NT, Kazansky A, LaFortune TA, Lucci A, Krishnamurthy S, Hung M-C, Hortobagyi GN, Woodward W, Reuben JM, Robertson F, Cristofanilli M, Zhang D. Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis. 2008 San Antonio Breast Cancer Symposium (#2042), 2008.
15. Mego M, De Giorgi U, Hsu L, Ueno N, Valero V, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M. Circulating tumor cells in metastatic inflammatory breast cancer. 2009 ASCO Annual Meeting. e-Pub 6/2009.
16. Debeb BG, Xu W, Hall CS, Ueno N, Reuben J, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli, Woodward WA. Cancer initiating cells downregulate microRNAs implicated in the regulation of epithelial mesenchymal transition (EMT). 2009 AACR Annual Meeting, 2009.
17. Mego M, Dawood S, De Giorgi U, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with non-detectable circulating tumor cells. 2009 San Antonio Breast Cancer Symposium (#3011), 2009.
18. Mego M, Mani S, Li C, Andreopoulou E, Tin S, Jackson S, Cohen EN, Gao H, Cristofanilli M, Reuben JM. Circulating tumor cells (CTCs) and epithelial Mesenchymal Transition (EMT) in breast cancer: Describing the heterogeneity of microscopic disease. 2009 San Antonio Breast Cancer Symposium (#3011), 2009.
19. Valero V, Bacus S, Mangalik A, Rabinowitz I, Arena F, Kroener JF, Curcio E, Watkins C, Magill P, Cristofanilli M. Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer. *Cancer Res* 69(Suppl. 2):246s (#3131), 2009.
20. De Giorgi U, Mego M, Rohren E, Valero V, Jackson S, Reuben JM, Macapinlac HA, Cristofanilli, Ueno NT. Circulating tumor cells and FDG-PET/CT for the therapeutic monitoring of bone metastases from breast cancer. 2009 San Antonio Breast Cancer Symposium (#1109), 2009.
21. Mego M, De Giorgi U, Hsu L, Andreopoulou E, Valero V, Dawood, S, Handy B, Reuben JM, Cristofanilli M. Circulating tumor cells and risk of venous thromboembolism in metastatic breast cancer patients. 2009 ASCO Annual Meeting (#1060), 2009.
22. Mego M, Gao H, Hartmann P, Xuemei W, Cohen EN, Alunni-Fabbroni M, Lee BN, Cristofanilli M, Reuben JM. Detection of microRNA genes in individual cancer stem cells from breast cancer cell lines using a single cell quantitative RT-PCR method. SABCs, 2009.
23. Reuben JM, Lee BN, Lucci A, Cohen EN, Li C, Krishnamurthy S, Hortobagyi GN, Woodward W, Cristofanilli M. Disseminated tumor cells in primary breast cancer: evaluation of the percentage of breast cancer stem cells in bone marrow aspirates of patients receiving neoadjuvant chemotherapy. 2009 ASCO Annual Meeting (#505), 2009.
24. De Giorgi U, Mego M, Handy BC, Jackson S, Reuben JM, Valero V, Cristofanilli M. Effect of trastuzumab and chemotherapy on circulating tumor cells in patients with poor prognosis metastatic breast cancer. 2009 San Antonio Breast Cancer Symposium (#3014), 2009.
25. Zhang X, Huang J, Lai Q, Li X, Moraes R, Wong H, Wiechmann L, Schiff R, Cristofanilli M, Krishnamurthy S, Reuben JM, Woodward WA, Chang JC, Lewis MT. Efficient generation of primary xenografts using normal and malignant human mammary epithelium in SCID/Beige mice without humanizing fibroblasts. 2009 AACR Annual Meeting, 2009.
26. Mego M, Li C, Lucci A, Mani S, Ueno NT, Cohen EN, Gao H, Tin S, De Giorgi U, Hortobagyi G, Cristofanilli M, Reuben JM. Epithelial mesenchymal transition (EMT) is involved in bone marrow dissemination of breast cancer cells. 2009 AACR Annual Meeting, 2009.
27. Reuben JM, Lee BN, Mego M, Gao H, Cohen EN, Li C, Andreopoulou E, Cristofanilli M, Mani SA. Epithelial Mesenchymal Transition (EMT) in breast cancer: Relationship to the functionality of dendritic cells. 7th International Meeting on Minimal Residual Disease, 2009.

28. Gao H, Cohen EN, Andreopoulou E, Ueno NT, Lee B-N, Parker C, Tin S, Jackson S, Cristofanilli M, Reuben JM. Immune profile of inflammatory breast cancer patients. 2009 San Antonio Breast Cancer Symposium (#4129), 2009.
29. Hall CS, Debeb B, Xu W, Robertson F, Reuben J, Ueno N, Cristofanilli M, Lucci A, Woodward WA. Inflammatory breast cancer cell line, MDA-IBC-1, expresses and secretes WISP3 a putative tumor suppressor in inflammatory breast cancer. 2009 AACR Annual Meeting, 2009.
30. Gao H, Cohen EN, Lee B-N, Andreopoulou E, Jackson SA, Parker CA, Tin S, Galland M, Ueno NT, Cristofanilli M, Reuben JM. Innate immune profile of inflammatory breast cancer patients. 2009 San Antonio Breast Cancer Symposium (#4129), 2009.
31. Mego M, De Giorgi U, Dawood S, Andreopoulou E, Valero V, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Kinetics of circulating tumor cells in metastatic breast cancer patients. 7th International Meeting on Minimal Residual Disease, 2009.
32. Mego M, Li C, Mani S, Ueno NT, Cohen EN, Gao H, Tin S, De Giorgi U, Champlin RE, Hortobagyi G, Cristofanilli M, Ueno NT, Reuben J. Loss of epithelial markers on CTC triggered by TWIST1 and SNAIL1 may lead to recurrent disease in breast cancer patients. 2009 AACR Annual Meeting, 2009.
33. Lee BN, Li C, Lucci A, Cohen EN, Gao H, Krishnamurthy S, Ueno NT, Hortobagyi GN, Cristofanilli M, Woodward WA, Reuben JM. Notch-1 expression is not related to the percentage of CD326+ vrlld in bone marrow aspirates of patients with primary breast cancer. SABCS, 2009.
34. Hall CS, Debeb BG, Xu W, Ueno NT, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward W. Novel inflammatory breast cancer cell line, MDA-IBC-1 expresses and secretes WISP3, a putative tumor suppressor in inflammatory breast cancer. SABCS, 2009.
35. Li C, Lee B-N, Woodward WA, Ueno NT, Robertson F, Reuben JM, Cristofanilli M. p53 mutation in inflammatory breast cancer cell lines. 2009 San Antonio Breast Cancer Symposium (#3161), 2009.
36. Mego M, De Giorgi U, Limin H, Dawood S, Andreopoulou E, Valero V, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Predictive value of circulating tumor cells (CTCs) in metastatic breast cancer patients treated by bevacizumab-based therapy. 2009 San Antonio Breast Cancer Symposium (#3013), 2009.
37. Robertson FM, Simeone A-M, Lucci A, Woodward W, Reuben JM, Ueno NT, Cristofanilli M. Role of the prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer. SABCS, 2009.
38. Robertson FM, Simeone AM, Lucci A, Woodward W, Reuben J, Ueno N, Cristofanilli M. Role of the prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer. *Cancer Res* 69(Suppl. 2):196s (#2127), 2009. Robertson F, Simeone A-M, Lucci A, Woodward W, Reuben J, Ueno N, Cristofanilli M. Role of the prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer. San Antonio Breast Cancer Symposium, December 11-16, 2008, 12/2008.
39. Robertson F, Woodward W, Bornmann W, Player A, Ye Z, Cristofanilli M. The pan- HDAC Inhibitor Suberoylanilide Hydroxamic Acid Targets Self Renewal of Breast Cancer Stem Cells, *Cancer Res* December 15, 2009; 69 (24 Supplement): 3141 poster at the CTRC-AACR San Antonio Breast Cancer Symposium, December 10-13, 2009.
40. Cohen EN, Lee B-N, Gao H, Andreopoulou E, Jackson SA, Parker CA, Tin S, Li Y-D, Galland MM, Cristofanilli M, Reuben JM. Soluble factors and circulating tumor cells in inflammatory breast cancer. 2009 San Antonio Breast Cancer Symposium (#2135), 2009.
41. De Giorgi U, Lucci A, Cohen EN, Gao H, Mego M, Li C, Cristofanilli M, Reuben JM. Subsets of mesenchymal stem cells correlate with breast cancer-propagating cells in bone marrow. 2009 AACR Annual Meeting, 2009.
42. Ueno NT, Kazansky A, LaFortune TA, Lucci A, Krishnamurthy S, Hung M-C, Hortobagyi GN, Woodward W, Reuben JM, Robertson F, Cristofanilli M, Zhang D. Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis. SABCS, 2009.
43. Lee B-N, Gao H, Cohen EN, Andreopoulou E, Jackson SA, Parker CA, Tin S, Galland MM, Ueno NT, Valero V, Alvarez RH, Cristofanilli C, Reuben JM. Patients with inflammatory breast cancer

- have significant reductions in immune cells responsible for adaptive immunity. *Cancer Research* 70 (#LB-314), 4/2010.
44. Giuliano M, Giordano A, Handy BC, Ueno NT, Alvarez RH, Hortobagyi GN, Reuben JM, Valero V, Cristofanilli M. Circulating Tumor Cells as Predictor of Metastatic Disease Spread in Patients with Breast Cancer. 2010 San Antonio Breast Cancer Symposium (#PD04-03), 12/2010.
 45. Giordano A, Giuliano M, Handy BC, Ueno NT, Alvarez RH, Cohen EN, Andreopoulou E, Reuben JM, Hortobagyi GN, Valero V, Cristofanilli M. Clinical Value of Circulating Tumor Cells (CTC) in First Line Metastatic Breast Cancer (MBC) Patients (pts) According to Type of Treatment and Immunohistochemical Molecular Subtype. 2010 San Antonio Breast Cancer Symposium (#PD04-02), 12/2010.
 46. Lee B-N, Gao H, Cohen EN, Tin S, Jackson SA, Valero V, Alvarez R, Cristofanilli M, Reuben JM. Dendritic Cells from Breast Cancer Patients with ≥ 5 CTCs Are Functionally Impaired. 2010 San Antonio Breast Cancer Symposium (#P3-02-04), 12/2010.
 47. Gao H, Lee B-N, Cohen EN, Mego M, Davis ML, Giordano A, Cristofanilli M, Ueno NT, Reuben JM. Detection of Circulating Tumor Cells Prior to Autologous Stem Cell Transplantation Is Predictive of Shorter Progression Free Survival in Metastatic Breast Cancer. 2010 San Antonio Breast Cancer Symposium (#P3-02-08), 12/2010.
 48. Anfossi S, Giordano A, Calin G, Cohen EN, Gao H, Galland M, Cristofanilli M, Lee B-N, Reuben JM. Higher Serum miR-21 Expression Correlates with Higher Levels of VEGF and bFGF in Patients with Metastatic Breast Cancer. 2010 San Antonio Breast Cancer Symposium (#P3-09-01), 12/2010.
 49. Alvarez RH, Cristofanilli M, Hsu L, Ueno NT, Alizadeh PA, Lucci A, Reuben JM, Buchholz TA, Hortobagyi GN, Valero V. Patient Characteristics and Clinical Outcome of Patients with Secondary Inflammatory Breast Cancer. M.D. Anderson Cancer Center, Retrospective Review. 2010 San Antonio Breast Cancer Symposium (#P5-15-03), 12/2010.
 50. Giuliano M, Giordano A, Handy BC, Ueno NT, Alvarez RH, Hortobagyi GN, Reuben JM, Valero V, Cristofanilli M. Prognostic Value of Circulating Tumor Cells (CTC) in HER-2 Positive Metastatic Breast Cancer (MBC) Patients (pts) Treated with Anti-HER2-Based Therapy. 2010 San Antonio Breast Cancer Symposium (#P3-02-03), 12/2010.
 51. Cohen EN, Gao H, Galland MM, Tin S, Jackson SA, Parker CA, Alvarez RH, Valero V, Ueno NT, Cristofanilli M, Lee B-N, Reuben JM. Serum Angiogenic Factors but Not TGF- β 1 Are Positively Correlated with CTC in Metastatic Breast Cancer Patients. 2010 San Antonio Breast Cancer Symposium (#P3-02-07), 12/2010.
 52. Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Reuben JM, Hortobagyi, De Placido S, Cristofanilli M. Circulating tumor cells (CTC) and artificial neural network (ANN) in metastatic breast cancer (MBC) patients. IMPAKT 2010 Conference Secretariat, 2010.
 53. Giuliano M, Giordano A, Hsu L, Handy B, Ueno N, Andreopoulou E, Alvarez RH, Valero V, Hortobagyi GN, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. AACR 101st Annual Meeting, 2010.
 54. Giuliano M, Giordano A, Handy B, Ueno NT, Andreopoulou E, Alvarez RH, Valero Vicente, Hortobagyi GN, Reuben JM, Cristofanilli M. Effect of reduction of circulating tumor cells (CTCs) on progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients. IMPAKT 2010 Conference Secretariat, 2010.
 55. Cohen EN, Gao H, Lee B-N, Andreopoulou E, Jackson SA, Parker CA, Tin S, Galland M, Ueno NT, Cristofanilli M, Reuben JM. Innate immune profile of inflammatory breast cancer patients. AACR 101st Annual Meeting 2010, 2010.
 56. Batty N, Cano P, Alizadeh P, Tin S, Jackson S, Lara J, Cristofanilli M, Reuben JM, Fernandez-Vina M. Innate immunity in inflammatory breast cancer (IBC) patients: Clues from HLA profiling. AACR 101st Annual Meeting 2010, 2010.
 57. Gao H, Cohen EN, Lee B-N, Andreopoulou E, Jackson SA, Parker CA, Tin S, Galland M, Ueno NT, Cristofanilli M, Reuben JM. T-cell cytokine production profile of breast cancer patients. *Blood* (##7493), 2010. Giordano A, Giuliano M, Hsu L, Handy B, Ueno N, Andreopoulou E, Alvarez R, Valero V, Hortobagyi G, Cristofanilli M. Prognostic value of circulating tumor cells (CTC) in

- metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. Proceeding ASCO 2010. Abstract #1000.
58. Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Reuben J, Hortobagyi G, De Placido S, Cristofanilli M. Circulating Tumor Cells (CTC) and Artificial Neural Network (ANN) in metastatic breast cancer (MBC) patients. Proceeding IMPAKT meeting 2010. Abstract #O25.
 59. Woodward WA, Cohen EN, Gao H, Li C, Jimenez C, Krishnamurthy S, Tucker SL, Cristofanilli M, Buchholz TA, Reuben JM. Use of fresh assessment of tumor-initiating cells in pleural fluid of breast cancer patients to predict overall survival. 2010 ASCO Annual Meeting (#1044), 2010.
 60. Giuliano M, Giordano A, Patt A, Hsu L, Alvarez RH, Ueno NT, Valero V, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer. 2011 ASCO Annual Meeting (#84009). e-Pub 6/2011.
 61. Giordano A, Mego M, Lee B-N, Anfossi S, Parker CA, Alvarez RH, Ueno NT, Valero V, Cristofanilli M, Reuben JM. Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer. 2011 ASCO Annual Meeting (#82279). e-Pub 6/2011.
 62. Cohen EN, Gao H, Lee BN, Lodhi AK, Krishnamurthy S, Ueno NT, Woodward WA, Cristofanilli M, Lucci A, Reuben JM. Primary breast cancer patients with high risk clinicopathologic features have high percentages of disseminated Aldefluor+ epithelial cells with CD44+CD24lo phenotype. 2011 DOD Era of Hope, 8/2011.
 63. Lee B-N, Cohen EN, Gao H, Galland M, Jackson S, Tin S, Cristofanilli M, Reuben JM. Detection of circulating tumor cells is associated with elevated serum inflammatory cytokines and derulated dendritic cells in breast cancer patients. 2011 San Antonio Breast Cancer Symposium (#74890), 12/2011.
 64. Reuben JM, Arun B, Lee B-N, Galland M, Cohen EN, Tin S, Nadeem M, Tang K, Yang MT, Gutierrez-Barrera AM, Kiyokawa I, Miura T, Valero V, Ueno NT, Cristofanilli M. Elevated serum levels of sialyl LewisX (sLeX) and inflammatory cytokines in patients with non-metastatic breast cancer. 2011 San Antonio Breast Cancer Symposium, 12/2011.
 65. Giordano A, Cohen EN, Anfossi S, Gao H, Lee B-N, Mego M, Tin S, Valero V, Alvarez RH, Cristofanilli M, DePlacido S, Hortobagyi GN, Woodward WA, Ueno NT, Reuben JM. Epithelial-Mesenchymal Transition correlated with serum cytokines profiling in breast cancer patients. 2011 San Antonio Breast Cancer Symposium, 12/2011.
 66. Lee BN, Shah N, Giralto S, Gao H, Cohen EN, Williams L, Gning I, Mendoza T, Brown J, Johnson VE, Champlin RE, Cleeland CS, Reuben JM. High dose autologous stem cell transplantation in multiple myeloma patients preserves inducible cytokine synthesis by activated peripheral blood leukocytes. 2011 ASH Annual Meeting, 12/2011.
 67. Anfossi S, Giordano A, Cohen EN, Gao H, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, Ueno NT, Lee B-N, Reuben JM. Higher expression levels of circulating miR-21, miR-19a and miR-10b are associated with high risk features in breast cancer. 2011 San Antonio Breast Cancer Symposium, 12/2011.
 68. Gao H, Cohen EN, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, Ueno NT, Reuben JM. Cytokine synthesis by activated dendritic cells in relation to disease progression in inflammatory breast cancer (IBC). 2011 San Antonio Breast Cancer Symposium, 2011.
 69. Cohen EN, Gao H, Galland M, Tin S, Jackson SA, Parker CA, Alvarez RH, Valero V, Ueno NT, Cristofanilli M, Reuben JM. Serum angiogenic factors but not TGF- β 1 are positively correlated with CTC in metastatic breast cancer patients. Trainee Research Day at MD Anderson Cancer Center, 2011.
 70. Cohen EN, Gao H, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, Ueno NT, Reuben JM. T-cell cytokine production related to progression of breast cancer patients. 2011 San Antonio Breast Cancer Symposium, 2011.
 71. S. J. Van Laere, N. T. Ueno, P. Finetti, P. B. Vermeulen, A. Lucci Jr., D. Birnbaum, F. Robertson, T. Iwamoto, P. A. van Dam, W. A. Woodward, P. Viens, L. Y. Dirix, J. M. Reuben, F. Bertucci. An integrated analysis of three distinct IBC/non-IBC affymetrix gene expression data sets to study the transcriptional heterogeneity both between IBC and non-IBC and within IBC. *J Clin Oncol* 29: 2011 (suppl; abstr 10571). 2011 ASCO Annual Meeting, June 3-7, Chicago, IL.

72. Robertson, FM, Petricoin, EF, Chu, K, Mu, Z., Boely, KB, Jin, J., Circo, R., Fernandez, SV, Alpaugh, RK, Wulfhuhle, J., Ye, Z., Wright, MC, Luo, AZ, Liu, H., Krishnamurthy, S, Sun, G., Zook, M, Barsky, SH and Cristofanilli, M. Gene amplification of Anaplastic Lymphoma Kinase in Inflammatory Breast Cancer. presented as a proferred paper (PR-4) at the 2011 AACR-NCI-EORTC meeting on Molecular Targets and Cancer Therapeutics, November 13, 2011, San Francisco, CA.
73. Van Laere, S, Ueno, NT, Finetti, P, Vermeulen, P, Lucci, A, Brinbaum, D, Robertson FM, Iwamoto, T, Van Dam, P, Woodward, WA, Viens, P, Dirix, L, Reuben, J and Bertucci, F. An integrated analysis of three distinct IBC/nIBC Affymetrix gene expression data sets: uncovering the molecular secrets of IBC biology. *Cancer Res.* 71 (24 Suppl), December 15, 124s, 2011. Presented as poster discussion at CTRC-AACR San Antonio Breast Cancer Symposium. December 6-10, 2011.
74. Chu, K., Boley, K.M., Luo, A.Z., Ye, Z., Wright, M.C., Freiter, E.M., Robertson, F.M. The reciprocal roles of E-cadherin and ZEB1 Demonstrate the Mesenchymal-Epithelial Transition As a Primary Characteristic of Inflammatory Breast Cancer. *Cancer Res.* 71 (24 Suppl), December 15, 162s, 2011. Presented as a poster at CTRC-AACR San Antonio Breast Cancer Symposium. December 6-10, 2011.
75. Liu H, Luo AZ, Mu Z, Chu K, Ye Z, Alpaugh RK, Fernandez S, Boley KM, Jin J, Wright MC, Cristofanilli M, Robertson FM. Genomic and proteomic pathway mapping of the specific gene families activated in the lymphangiogenesis and vasculogenic mimicry exhibited by inflammatory breast cancer. *Cancer Res;* 71 (24 Suppl.) December 15, 262s, 2011. Presented as a poster at CTRC-AACR San Antonio Breast Cancer Symposium. December 6-10, 2011.
76. Chu, K., Mu, Z., Alpaugh, R.K., Fernandez, S., Freiter, E.M., Wu, H., Zook. M.B., Barsky, S.H., Cristofanilli, M. and Robertson, F.M. Development and Comparative Characterization of Metastasis in Newly Developed Pre-clinical Models of Inflammatory Breast Cancer. *Cancer Res;* 71 (24 Suppl.) December 15, 439s, 2011. Presented as a poster at CTRC-AACR San Antonio Breast Cancer Symposium. December 6-10, 2011.
77. Robertson, F.M., Ye, Z., Chu, K., Luo, A.Z., Wright, M.C., Jin, J., Barsky, S.H., Cristofanilli, M., and Krishnamurthy, S. Secretory Leukocyte Protease Inhibitor as a Differential Diagnostic Biomarker of Tumor Emboli in Inflammatory Breast Cancer. *Cancer Res;* 71 (24 Suppl.) December 15, 459s, 2011. Presented as a poster at CTRC-AACR San Antonio Breast Cancer Symposium. December 6-10, 2011.
78. Robertson, FM, Petricoin, EF, Chu, K, Mu, Z, Jin, J, Circo, R, Fernandez, S, Alpaugh, RK, Zook, M, Sun, G, Wulfkuhle, J, Liotta, Ye, Z, Krishnamurthy, S, Luo, AZ, Liu, H, Wright, MC, Barsky, SH and Cristofanilli, M. Amplification of Anaplastic Lymphoma Kinase (ALK) as a common genetic alteration in Inflammatory Breast Cancer. *Cancer Res;* 71 (24 Suppl.) December 15, 37s, 2011. Presented as a poster at CTRC-AACR San Antonio Breast Cancer Symposium. December 6-10, 2011.
79. Fernandez SV, Mu Z, Aburto L, Dong, X., Chu, K., Boley, K., Berditchevski, F., Robertson, F., Cristofanilli, M.: FC-IBC-02: A new in vitro-in vivo model of inflammatory breast cancer (IBC). *AACR Proceedings* 53: 1291 Abstract No 5342, 2012.
80. Zhaomei Mu, Hua Li, Rugang Zhang, Massimo Cristofanilli, EZH2 Knockdown suppresses the growth of human inflammatory breast cancer cells both *in vitro* and *in vivo* in xenograft models. *AACR Proceedings* 53: Abstract No LB-387, 2012.
81. Cristofanilli M, Stephen R. D. Johnston, Alexey Manikhas, Henry Leonidas Gomez, Oleg Gladkov, Zhimin Shao, Sufia Safina, Stephen D. Rubin, Sulabha Ranganathan, Suman Lata, Maureen E. Trudeau; randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).(Poster Discussion), *Proceeding ASCO 2012 Abstract #531. J Clin Oncol* 30, 2012 (suppl; abstr 531)
82. Lisette Stork-Sloots, Katharine Yao, Mary Turk, Karen Kaul, JoEllen Weaver, Femke De Snoo, Massimo Cristofanilli. Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U.S. breast cancer (BC) patients. *Proceeding ASCO 2012 Abstract #577. J Clin Oncol* 30, 2012 (suppl; abstr 577)
83. Ricardo H. Alvarez, Massimo Cristofanilli, Joe Ensor, Anthony Lucci, Wei Tse Yang, Huong T. Le-Petross, James M. Reuben, Gildy Babiera, Lei Huo, Yun Gong, Wendy A. Woodward, Charla A. Parker, Jie S. Willey, Thomas A. Buchholz, Naoto T. Ueno, Vicente Valero. Limited efficacy and

- significant toxicities of lapatinib (Lap) plus chemotherapy as neoadjuvant therapy (NAC) for HER2-positive inflammatory breast cancer (IBC) patients (Pts). Proceeding ASCO 2012 Abstract #594. *J Clin Oncol* 30, 2012 (suppl; abstr 594)
84. Yao K, Turk M, Kaul K, Weaver JE, De Snoo F, Stork-Sloots L, Cristofanilli M. Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in US breast cancer (BC) patients. 2012 ASCO Breast Meeting (poster discussion)
 85. Cristofanilli M, Alpaugh KR, Ross J, Bingham C, Wu H, Stephens P, Lipson D, Palmer G. Next generation genomic sequencing (NGS) identifies molecular targets in inflammatory breast cancer (IBC). *Cancer Res*, 72(24), Suppl, Decemebr 2012: abstract PD5-01(124s);
 86. Alpaugh RK, Bingham C, Fittipaldi P, Banzi M, Palmer G, Cristofanilli M. What is the appropriate sample (s) on which to perform sequencing for mutational analysis to guide the selection of targeted therapy? *Cancer Res*, 72(24), Suppl, Decemebr 2012: abstract PD5-03(125s);
 87. Moulder S.L., E. Rivera, Ensor J., Gonzalez-Angulo, Cristofanilli M. et al. Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC). 2009 ASCO Annual Meeting.
 88. Woodward W.A, Cohen E.N, Gao H., Li L., Krishanuthy S., Cristofanilli M., et al. Use of fresh assessment of tumor-initiating cells in pleural fluid of breast cancer patients to predict overall survival. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 1044).
 89. Alvarez R.H., Banchini L., Hsu L., Cristofanilli M., et al. The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M.D. Anderson Cancer Center retrospective analysis. *J Clin Oncol* 28:15s, 2010.
 90. Giordano A., Guiliano M., Hsu L., Handy C., Ueno N.T., M. Cristofanilli, et al. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. *J Clin Oncol* 28:15s, 2010(suppl;abstr 1000)
 91. Guiliano M., Giordano A., Hsu L., Handy B.C., Ueno N.T., Cristofanilli M., et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first line therapy. *J Clin Oncol* 28:15s, 2010(suppl;abstr 1033).
 92. Patt A., Li T., Cristofanilli M., Freedman G.A., Sigurdson E.R., Bleicher R.J. Clinical significance of time relapse and the distinction between breast cancer recurrences and new primary tumors. *J Clin Oncol* 29:2011 (suppl;abstr 1071).
 93. Guilano M., Giodano A., Patt A., Hsu L., Cristofanilli M. et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first line therapy. *J Clin Oncol* 29, 2011(suppl;abstr 610).
 94. Giordano A., Mego M., Lee B., Anfossi S., M. Cristofanilli. Et al., Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer. *J Clin Oncol* 29:2011 (suppl;abstr623).
 95. Liu M.C., Mego M., Nakamura S., Nde F., M. Cristofanilli, et al. Clinical validity of circulating tumor cell (CTC)enumeration in 841 subjects with metastatic breast cancer (MBC). *J Clin Oncol* 29:2011 (suppl;abstr10592).
 96. Reuben J.M., Arun B., Lee B., Galland M., Cohen E.N., Tin S., Nadeem M., Yang M.T., Cristofanilli M., et al. Elevated serum levels of Sialyl Lewis X (sLeX) and inflammatory cytokines in patients with nonmetastatic breast cancer. *J Clin Oncol* 29:2011 (suppl;abstr e11061).
 97. Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A., Birnbaum D., Robertson FM, van Dam PA, Woodward WA., Viens P, Dirix LY, Cristofanilli M. et al. An integrated analysis of three distinct IBC/nIBC affymetrix gene expression data sets further unveils the molecular biology of IBC. San Antonio Breast Symposium December 2011.
 98. Giodano A., Cohen EN, Afossi S. Gao H., Lee B-N, Mego M., Sanda T., Valero V., Alvarez RH, Cristofanilli M. Epithelial-mesenchymal transition correlated with serum cytokine profiling in breast cancer patients. . San Antonio Breast Symposium December 2011
 99. Liu H., Luo AZ, Mu Z, Chu K., Ye Z., Alpaugh RK, Fernandez S., Boley KM, Jin J., Cristofanilli M. et al. Mapping the specific gene families activated in the lymphangiogenesis and vasculogenic mimicry exhibited by inflammatory breast cancer. . San Antonio Breast Symposium December 2011.

100. Robertson FM, Petricoin EF, Chu K., Mu Z, Jin J., Circo R., Fernandez SV., Alpaugh RK, Zook M, Sun G., Wulfkuhle J., Liotta LA, Ye Z, Krishnamurthy S., Luo AZ, Lui H., Cristofanilli M. et al. Amplification of anaplastic lymphoma kinase (ALK) as a common genetic alteration in inflammatory breast cancer. . San Antonio Breast Symposium December 2011.
101. Anfossi S., Giodano A., Cohen EN, Gao H., Cristofanilli M. et al. Higher expression levels of circulating miR-21, MiR-19a and miR-10b are associated with high risk features in breast cancer. . San Antonio Breast Symposium December 2011.
102. Robertson FM., Chu K., Mu Z, Boley KM, Green TL, Moraes R., Zhang X, Alpaugh RK, Basby A, Ye Z, Wright MC, Liu H, Luo AZ, Barsky SH, Heise C., Cristofanilli M. Romidepsin inhibits growth and metastasis and is synergistic with paclitaxel in pre-clinical models of inflammatory breast cancer.
103. Cristofanilli M., et al. A randomized phase II study (VEG108838) of lapatinib plus pazopanib (L+P) versus lapatinib (L) in patient with ErbB2+ inflammatory breast cancer. (IBC). 2012 ASCO Annual Meeting. #531. J Clin Oncol 30, 2012(suppl; abstr 531).
104. Stork-Slods L., Yao K., Turk M, Kaul K., Weaver J., Cristofanilli M., et al. Molecular subtyping using MammPrint and Blue Print as an outcome predictor in 180 U.S. breast cancer (BC) patients. 2012 ASCO annual meeting. J Clin Oncol 30, 2012(suppl; abstr 577).
105. Alvarez R.H., Cristofanilli M., Ensor J., Lucci A., Yang Tse W., Le-Petross H.T, Limited efficacy and significant toxicities of lapatinib (Lap) plus chemotherapy as neoadjuvant therapy (NAC) for HER2-positive inflammatory breast cancer (IBC) patients (Pts). 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl;abstr594).
106. Cristofanilli M., Alpaugh KR, Ross J., Bingham C., Wu H, Stephens P, Lipson D, Palmer G. Next Generation Genomic Sequencing (NGS) Identifies Molecular Targets in Inflammatory Breast Cancer(IBC). San Antonio Breast Dec. 6; 2012.
107. Alpaugh RK., Bingham C., Fittipaldi P., Banzi M., Palmer G., Cristofanilli M. What is the Appropriate Sample (S) on which to perform sequencing for Mutational Analysis to guide the Selection of Target Therapy?. San Antonio Breast Cancer Symposium December 2012.
108. Giodano A., Reuben JM, Egleston BL, Hajage D., Hortobagyi GN, Cristofanilli M. et al. Establishment and validation of circulating tumor cell-based prognostic nomogram in 497 first-line metastatic breast cancer patients. San Antonio Breast Cancer Symposium December 2012.
109. Giodano A., Gao H., Cohen EN, Anfossi S., Hess KR, Krishnamurthy S., Tin S., Cristofanilli M. et al. Identification of cancer stem cells (CD44+CD24-/lo) in bone marrow as a prognostic factor in early breast cancer patients. San Antonio Breast Cancer Symposium December 2012.
110. Lee B-N, Arun BK, Cohen EN, Tin S., Gutierrez-Barrera AM, Miura T., Kiyokawa I, Alvarez RH, Valero V., Ueno NT, Cristofanilli M. et al. Sialyl Lewis^x and Inflammatory mediators in Breast Cancer patients: Biological correlations and prognostic value. San Antonio Breast Cancer Symposium December 2012.
111. Cristofanilli M., Turk M., Kaul K., Weaver J., Wesseling J, Stork-Slouts L., de Snoo F., Yao K. Molecular subtyping improves stratification of patients into diagnostically more meaningful risk groups. San Antonio Breast Symposium December 2012.
112. Fernandez S., Aburto L, Maggi R., Breitschwerdt EB, Cristofanilli M. Bartonella Henselae infection detected in patients with inflammatory breast cancer. San Antonio Breast Symposium December 2012.
113. Robertson FM., Hibbs S., Boley KM, Chu K, Ye Z., Wright MC, Liu H., Luo AZ, Cristofanilli M. Zinc finger nuclease genome engineering reveal multiple functions of secretory leukocyte peptidase in regulating pluripotency of cancer stem cells in inflammatory breast cancer. San Antonio Breast Symposium December 2012.
114. Chu K., Boley KM, Cristofanilli M., Robertson FM. E-Cadherin is required for in vivo growth of inflammatory breast cancer: Importance of mesenchymal-epithelial transition (MET) and role of HIF1a. San Antonio Breast Symposium December 2012.
115. Anfossi S., Giordano A., Cohen EN, Gao H., Woodward W., Ueno NT, Valero V., Alvarez RH, Hortobagyi GN, Cristofanilli M. High Serum levels of miR-19a are associated with poor outcome in metastatic inflammatory breast cancer. San Antonio Breast Symposium December 2012.

116. Dong X, Franco-Barraza J., Mu Z., Alpaugh RK, Cristofanilli M., Cukierman E. A novel culturing 3-D model to evaluate the role of tumor microenvironmental in IBC. San Antonio Breast Symposium December 2012.
117. Liu H., Chu K., Ochoa AE, Ye Z, Zhang X, Jin J., Wright MC, Cristofanilli M. et al. The presence of anaplastic lymphoma kinase recapitulates formation of breast tumor emboli with encircling lymphovasculogenesis. San Antonio Breast Symposium December 2012.
118. Schott AF, Wicha M, Cristofanilli M. et al. Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer. San Antonio Breast Symposium December 2012.
119. Cristofanilli M. Inflammatory breast cancer: Diagnosis, treatment and biology. San Antonio Breast Symposium December 2013.
120. Jeelsohn RM., Yelensky R., Buchwalter G., Frampton G., Meric-Bernstam F., Cristofanilli M., et al. Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer. San Antonio Breast Symposium December 2013.
121. Mego M., Karaba M., Minarik G, Benca J., Sedlackova T., Tothova L., Vikova B., Cierna Z., Janega P, Manasova D., Luha J, Gronsova P, Pechan J., Fridrichova I, Celec P., Reuben JM, Cristofanilli M. Correlation between blood markers of hemostasis and circulating tumor cells (CTC) in early breast cancer patients. San Antonio Breast Symposium December 2013.
122. Van Laere SJ., Marsan M., Vermeulen PB, Viens P, Barsky SH, Cristofanilli M., et al. Comparative expression profiling of patient samples and preclinical models of inflammatory breast cancer reveals gene signatures of epithelial plasticity and suppression of TGF β signaling. San Antonio Breast Symposium December 2013.
123. Yao K, Turk M., Kaul K, Wesseling J., Stork-Sloots L, de Snoo F., Cristofanilli M. MammaPrint and Blueprint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping. San Antonio Breast Symposium December 2013.
124. Mu Z., Brown MV, Fernandez S., Robertson FM., Cristofanilli M. Metabolomic analysis of breast cancer cell lines: Clues to the metabolic fingerprint of inflammatory breast cancer. San Antonio Breast Symposium December 2013.
125. Hashmi S., Liu Y, Bethony J, Cristofanilli M., Levine PH. Seasonal variation in onset of inflammatory breast cancer: Evidence of an infectious trigger. San Antonio Breast Symposium December 2013.
126. Dawood S., Lei X, Dent R., Gupta S., Sirohi B., Cortes J., Cristofanilli M. et al. Survival of women with inflammatory breast cancer: A large population based study. San Antonio Breast Symposium December 2013.
127. Fernandez SV., Alpaugh RK., Aburto L., He J., Nahas M., Otto G., Stephens P., Palmer G., Cristofanilli M., Lipson D. Prevalence of propionibacterium acnes and bartonella henselae DNA in patients with inflammatory breast cancer. San Antonio Breast Symposium December 2013.
128. Chu K., Green TL, Boley KM, Cristofanilli M., Robertson FM. Histone deacetylase inhibitor suberoylanilide hydroxamic acid targets breast cancer stem cells and inhibits metastasis. San Antonio Breast Symposium December 2013.
129. Goldstein LJ, Sparano J, Perez RP, Vito C., Reuben JM, Landis MD., McCanna S., Ruffini PA, Cristofanilli M., Chang JC. A single arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery. San Antonio Breast Symposium December 2013.
130. Turner N., Andre F., Loibl S., Ro J., Iwata H, Harbeck N., Gluck S., Verma S., Loi S, Huang Bartlett C., Thiele A., Zhang K, Koehler M, Cristofanilli M. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) + goserelin in women with hormone receptor-positive, HER2 negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy. San Antonio Breast Symposium December 2013. San Antonio Breast Cancer Symposium December 2011.
131. Chu K, Mu Z, Alpaugh RK, Fernandez SV, Frieter EM, Wu H, Zook MB, Barsky SH, Cristofanilli M. et al. Development and Comparative characterization of metastasis in newly developed pre-clinical models of inflammatory breast cancer. San Antonio Breast Cancer Symposium December 2011.

132. Mego M., Giodano A, De Giogi U, Hsu L, Lucci A., Dawood S., Woodward WA, Ueno NT, Valero V., Andreopoulou E, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in newly diagnosed inflammatory breast cancer. San Antonio Breast Cancer Symposium December 2011.
133. Robertson FM, Ye Z, Chu K., Luo AZ, Wright MC, Jim J, Barsky SH, Cristofanilli M., Krishnamurthy S. Secretory Leukocyte protease inhibitor as a differential diagnostic biomarker of tumor emboli in inflammatory breast cancer. San Antonio Breast Cancer Symposium December 2011.
134. Lubbe W., Li T, Hughes M., Ottesen R., Cristofanilli M et al. Inflammatory breast cancer (IBC) in the National Comprehensive Cancer Network (NCCN): The Disease, the recurrence pattern and the outcome. San Antonio Breast Cancer Symposium December 2011.
135. Cohen EN, Gao H., Lee B-N, Giodano A., Tin S, Anfossi S., Parker CA , Cristofanilli M. et al. T-Cell cytokine production related to progression of breast cancer patients. San Antonio Breast Cancer Symposium December 2011.
136. Gao H, Cohen EN, Lee B-N, Giodano A., Tin S, Parker CA, Cristofanilli M. et al. Cytokine synthesis by activated dendritic cells in relation to disease progression in inflammatory breast cancer(IBC). San Antonio Breast Cancer Symposium December 2011.
137. Yamauchi H., Natori A. Hayashi N, Soejima K, Takahashi O, Fukui T., Nakamura S., Cristofanilli M., et al. Inflammatory breast cancer: Comparison of epidemiology, biology and prognosis between Japan and the United States a hospital based study. San Antonio Breast Cancer Symposium December 2011.
138. Boland P.M., Skabnik AP., Cristofanilli M., Alpaugh R.K., Olszanski J. Application of next-generation sequencing (NGS) for evaluation of advanced epithelial cancers:A single institution experience. 2013 ASCO Annual Meeting. J Clin Oncol 31, 2013 (suppl;abstr 11092).
139. Strauss W., Dempsey P.W, Winer-Jones J., Bingham C., Alpaugh R.K., Cristofanilli M. Classifying circulating, mutation bearing tumor cells from breast cancer patients. 2013 ASCO annual meeting. J Clin Oncol 31, 2013(suppl;abstract 580).
140. Ross J.S., Cristofanilli M., Downing S., Yelensky R., Lipson D., Otto G. Palmer G.A., et al. Use of Foundation One next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer. 2013 ASCO annual meeting. J Clin Oncol 31, 2013(suppl;abstract 1009).
141. Johnston S.R.D., Basik M., Hegg R. Lausootomski W., Gzeda L., Clemons M., Crisofanilli M. et al. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naïve advanced breast cancer (MINT). 2013 ASCO annual meeting. J Clin Oncol 31, 2013(suppl;abstract 531).
142. Avery TP., Austin L., Andre-Sendecki J., Fouad T. M., Giordano A., Reuben JM., Jaslow R., Crisofanilli M. et al. Circulating tumor cells (CTCs) in metastatic breast cancer. Ethnicity and disease subtypes. 2014 ASCO Annual Meeting. J Clin Oncol 31, 2013(suppl;abstract e22027).
143. Austin LK., Fortina P., Sebisanoovic D., Stew L., Zapanta A., Talasaz AA., Cristofanilli M. Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC). 2014 ASCO annual meeting. J Clin Oncol 31, 2013(suppl;abstract 11093).
144. Rodriguez J., Limentani K., Andre-Sendecki J., Hyslop T., Cristofanilli M., Jaslow R., Avery TP. Mitchell EP. Breast cancer in young women: A single center study. 2014 ASCO Annual Meeting. J Clin Oncol 31, 2013(suppl;abstract 595).
145. Jiang Z., Li L., Zhang S., Wang T, Liu Y., Ban L., Yang Y., Cristofanilli M. Predictive value of CTCs biomarkers status in patients with metastatic breast cancer (MBC) receiving anti-HER2 therapy. 2014 ASCO annual meeting. J Clin Oncol 31, 2013(suppl;abstract 628).
146. Lin J., Sama AR., Hoffman-Centis J., Kilpatrick D., Yang H., Mu Z., Lieby B., Lewis N., Crisofanilli M., Kelly WK. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone. 2014 ASCO Annual Meeting. J Clin Oncol 31, 2013(suppl;abstract TIPS5107)
147. Adams D., Bergan R., Ogden IM., Alpaugh RK., Cristofanilli M. et al. A pilot study detailing cancer-specific biomarkers in giant macrophages mimicking circulating tumor cells in the

- circulation of cancer patients. 2014 ASCO annual meeting. . J Clin Oncol 31, 2013(suppl;abstract e22015).
148. Berger AC., Guiles F, Toss A., SEndecki JA., Simone NL, Anne PR., Avery TP., Jaslow RJ., Palazzo J., Lazar MA, Tsangaris TN, Cristofanilli M. Ductal carcinoma in situ (DCIS): Ethnicity, clinical-pathologic features, and outcome. 2014 ASCO Meeting. . J Clin Oncol 31, 2013(suppl;abstract e11503).
 149. Rodriguez J, Patel S., Alpaugh RK., Palazoo J., Berger AC., Avery TP., Jaslow RJ., Anne PR., Simone NL., Tsangaris TN., Cristofanilli M. A retrospective review of clinical and pathologic aspects of inflammatory breast cancer: Clues for risk-adapted monitoring and therapy. 2014 ASCO meeting. . J Clin Oncol 31, 2013(suppl;abstract e11506).
 150. Goptu M., Doval D., Kumar K., Dewan A., Mehta A., Batra U., Dutta K., Avery TP, Jaslow RJ., Mitchell EP., Nayer A., Manavalan J., Crisofanilli M. Breast cancer in low-income countries: India as a model. 2014 ASCO annual meeting. . J Clin Oncol 31, 2013(suppl;abstract e17517).
 151. Adams D., Martin SS, Charpenter M, Chumsri S., Bergan RC. Ogden IM, Alpaugh K, Cristofanilli M, Tsai S., Makarova OV, Zhu P., Cristofanilli M., et al. A pilot study identifying cancer-associated macrophage-like cells in the blood of cancer patients. 2014 ASCO annual meeting. . J Clin Oncol 31, 2013(suppl;abstract e22014).
 152. Austin L., Fortina P., Sebisanoovic D., Siew L., Zapanta A., Schiller BJ., Mei G., Eltoukhy H., Talasaz A., Cristofanilli M. Circulating tumor DNA (ctDNA) Provides Molecular Monitoring for Inflammatory Breast Cancer (IBC). Affiliation Guardant Health Inc. San Antonio Breast Conference 2014.
 153. Adams DL., Martin SS., Chumsri S., Charpentier R., Alpaugh K., Cristofanilli M., Tang CM, Haudenschild CC. Applying a mitotic index to circulating tumor cells and its prognostic significance: A cytological approach to patient stratification. 2015 ASCO Annual Meeting J Clin Oncol 33, 2015. (sup; abstr 11029).
 154. Adams DL., Bergan RC., Martin SS., Chumsri S., Charpentier M., Rena G., Lapidus R., Alpaugh K., Cristofanilli M., Tsai S., Tang C-M, Edelman MJ. Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies. 2015 ASCO Annual Meeting.

Book Chapters

1. Buzdar A, Cristofanilli M, Diamandidou E. Aspetti clinici. In: Carcinoma Della Mammella. Ed(s) A Halliwell, A Buzdar, 61-70, 1999.
2. Buzdar A, Cristofanilli M, Hortobagyi GN. Carcinoma infiammatorio. In: Carcinoma Della Mammella. Ed(s) A Bonifacino, M Halliwell, A Buzdar, 296-306, 1999.
3. Buzdar A, Cristofanilli M, Pro B. Fratture patologiche. In: Carcinoma Della Mammella. Ed(s) A Bonifacino, M Halliwell, A Buzdar, 353-355, 1999.
4. Buzdar A, Cristofanilli M, Pro B. Manifestazioni del sistema nervoso centrale. In: Carcinoma Della Mammella. Ed(s) A Bonifacino, M Halliwell, A Buzdar, 347-352, 1999.
5. Buzdar A, Cristofanilli M. Terapia Endocrina. In: Carcinoma Della Mammella. Ed(s) A Bonifacino, M Halliwell, A Buzdar, 307-320, 1999.
6. Cristofanilli M, Newman L, Hortobagyi GN. Breast cancer risk and management: Chemoprevention, surgery, and surveillance. In: Breast Cancer Atlas of Clinical Oncology. Winchester Ed, 19-40, 2000.
7. Cristofanilli M, Esteva F. Occult micrometastasis in bone marrow and blood. In: Advanced Therapy of Breast Disease, 2, Chapter 48. Ed(s) SE Singletary, GL Robb, GN Hortobagyi. BC Decker Inc., 489-497, 2004.
8. Esteva FJ, Fritsche HA, Reuben JM, Cristofanilli M. Serum tumor markers and circulating tumor cells. In: M. D. Anderson Cancer Care Series: Breast Cancer, 2, Chapter 10. Ed(s) KK Hunt, GL Robb, EA Strom, NT Ueno, G Robb. Springer: New York, 309, 2007.
9. Reuben JM, Cristofanilli M. Circulating tumor cells in individualizing breast cancer. In: Pharmacogenetics of Breast Cancer: Towards the individualization of therapy. 11. Informa Healthcare: New York, 151-166, 2008.

10. Cristofanilli M. Inflammatory breast cancer: The challenges ahead. In: Breast Diseases. 20, 1. Elsevier: St. Louis, 34-35, 2009.

11. Robertson FM, Chu K, Circo R, Wulfkuhle, Liotta L, Luo AZ, Boley KM, Freiter EM, Liu H, Mandal PK, McMurray JS, Cristofanilli M, Petricoin EF. Inflammatory mediators as therapeutic targets for Inflammatory Breast cancer. Springer SBM-185-206, 2012

Books (edited and written)

Naoto T Ueno and Massimo Cristofanilli: "*Inflammatory Breast Cancer: An Update*" -Springer SBM NL 4-12

Massimo Cristofanilli: "*Liquid Biopsies*" – Springer, 3/17

Letters to the Editor

1. Cristofanilli M, Singletary ES, Hortobagyi GN. Inflammatory breast carcinoma: The sphinx of breast cancer research. J Clin Oncol 15(22):381-383, 2004.

2. Gonzalez-Angulo A, Morandi P, Cristofanilli M. Inflammatory breast cancer and high-dose chemotherapy: Back to the past. J Clin Oncol 23(16):3859-3860, 2005.

3. Cristofanilli M, Reuben J, Uhr J. Circulating tumor cells (CTCs) in breast cancer: Fiction or reality? JCO 26(21):3656-3657, 2008. PMID:18640950.

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Contributing Editor, Breast Disease, 2004–present

Guest Editor, Seminars Oncol, 2008

Guest Editor, CA Journal for Oncologist, 2009

Member of Editorial Review Board

Current Drug Discovery Technologies, Bentham Science Publishers Ltd., 2007–2010

Journal of Oncology, 2009-present

Journal Reviewer

Journal Reviewer, Breast Cancer Research and Treatment, 2004–present

Journal Reviewer, Cancer, 2004–present

Journal Reviewer, Clinical Breast Cancer, 2004–present

Journal Reviewer, Clinical Cancer Research, 2004–present

Journal Reviewer, Expert Opinion in Target Therapeutics, 2004–present

Journal Reviewer, Expert Opinion in Therapeutic Patents, 2004–present

Journal Reviewer, Gynecological Endocrinology, 2004–present

Journal Reviewer, Journal of Clinical Oncology, 2004–present

Journal Reviewer, Journal of Surgical Oncology, 2004–present

Journal Reviewer, New England Journal of Medicine, 2005-present

Journal Reviewer, Nature Medicine (ad-hoc) 2006-present

Journal Reviewer, Cancer Research, 2006-present

Journal Reviewer, JAMA, 2008-present

Journal Reviewer, Lancet Oncology, 2008-present

TEACHING

The University of Texas M.D. Anderson Cancer Center

Fox Chase Cancer Center

Thomas Jefferson University

Northwestern University

Training Programs

Chair, Seminar in Nuclear Medicine: Gene therapy in breast cancer, The University of Texas M.D. Anderson Cancer Center, Houston, TX 4/2003

Chair, Breast Cancer Research Group Summer Retreat: Signal transduction modulation in breast cancer. Opportunities and limitations, The University of Texas M. D. Anderson Cancer Center, Houston, TX 5/2003

Co-Chair and Founder of the 1st International Conference on Inflammatory Breast Cancer, Houston, 12/08

Chair, 1st Breast Cancer Research retreat, Fox Chase Cancer Center, 10-2011

Co-Chair- 3rd International Conference on IBC, Philadelphia, 12/12

Co-Chair- 5th International Conference on IBC, Boston, 7/16

Co-Chair- 1st OncoSET Precision Medicine Conference, 4/17

Co-Chair- 2nd OncoSET Precision Medicine Conference 5/18

Co-Chair- 6th International Conference on IBC, Madrid, Spain, 9/18

Co-Chair- 3rd OncoSET Precision Medicine Conference, Chicago, April 2019

Co-Chair of the 1st North Africa IBC meeting, Tunis, September 2019

Other Formal Teaching

Lecturer, Inflammatory breast cancer research program and the evolution of multidisciplinary research: Back from the future? The University of Texas M. D. Anderson Cancer Center, Houston, TX 9/2008

Lecturer, Inflammatory breast cancer: The path to personalized therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX 11/2008

Supervisory Teaching

Committees

Advisory Committees

Betsy Plimack, Adam Cohen, Department Medical Oncology, Fox Chase Cancer Center-2010-2013

Rugang Zhang, PhD- Women Cancer Program, Fox Chase Cancer Center-2010-2013

Direct Supervision

Joan Lewis-Wambi, PhD, Women Cancer Program, Fox Chase Cancer Center-2010-Present

Sandra Fernandez, PhD- IBC laboratory- Women Cancer Program, Fox Chase Cancer Center-2010-Present

Zhaomei Mu, MD - Women Cancer Program, Fox Chase Cancer Center-2010-Present

Xiasheng Dong, MD- Visiting Scientist IBC laboratory- Women Cancer Program, Fox Chase Cancer

Katherine Alpaugh, PhD- Director of the CTC Center of Excellence, Women Cancer Program, Fox Chase Cancer Center-2011-Present

Aburto Lucy, PhD, IBC Laboratory, Women Cancer Program, Fox Chase Cancer Center-2010-2012
Benadetta Pellegrino, M.D., International Observer from Italy
Angela Toss, M.D.- Visiting Scientist from Italy
Giovanna Rossi MD, Visiting Scientist from Italy
Lorenzo Gerratana MD, Visiting Scientist from Italy
Ami Shah, Breast Cancer Junior Faculty, Luire Cancer Center
Andrew Davis, Medical Oncology fellow, Lurie Cancer Center
Carolina Reduzzi, Visiting Scientist from INT, Milan

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

Cohen EN, PhD, The University of Texas, MD Anderson Cancer Center, 2008-2010
Dai Horiuchi, PhD, Northwestern University, 2017-
Xia Lin, PhD, Northwestern University, 2017-

Clinical Residents and Fellows

Research Mentor, Dr. Ana-Maria Gonzalez-Angulo, 2003–2004 (UTMDACC-Medical Oncology Fellow)
Research Mentor, Dr. Paolo Morandi, 2003–2004 (Visiting Scientist- Vicenza Oncology Service)
Research Mentor, Dr. Silwan Chedid, 2003–2004 (UTMDACC- Medical Oncology Fellow)
Research Mentor, Dr. Shaheenah Dawood, 2006–2007 (Susan Komen Fellow-Dubai Hospital)
Research Mentor, Dr. Mario Giuliano, 2009-11 (PostDoc training-University of Naples)
Research Mentor, Dr. Antonio Giordano, 2009-current (PostDoc training-University of Naples) -
AACR fellow award (2012), ASCO YIA (2012)
Research Mentor, Dr. Andrew Davis, 2016-present
Research Mentor, Dr. Adam Lin, 2017-present
Research and Clinical Mentor, Ami Shah, MD, 3-2018-present
Research and Clinical Mentor, Andrew Daviss, 1/2019-present

Teaching Outside of Current Institution

Formal Teaching

Courses Taught

Lecturer, NOCR - San Antonio Breast Cancer Highlights Meeting, NOCR
1/2003
Lecturer, Promising molecular targets in breast cancer, School of Breast Oncology
11/2003

Other Formal Teaching

Lecturer, New frontiers in the management of primary and metastatic breast cancer, Beth Israel Hospital-Harvard Medical School, Boston, MA 3/2002

Lecturer, The evolution in the medical management of primary breast cancer, Henry Ford Hospital, Detroit, MI 3/2002

Lecturer, Maximizing metastatic breast cancer treatment and outcomes through cell-based disease monitoring and anemia management, Northwestern Memorial Hospital, Chicago, IL 8/2006

Lecturer, Inflammatory breast cancer update, The University of Texas M. D. Anderson Cancer Center, Orlando, FL 1/2007

Lecturer, Circulating tumor cells (CTCs) in breast cancer patients: Prognosis, prediction and beyond, Dartmouth Hitchcock Medical Center, Lebanon, NH 3/2007

Lecturer, Inflammatory breast cancer: Diagnostic and treatment challenges, Presbyterian Healthcare Hospital, Albuquerque, NM 3/2008

Lecturer, Fellows Lecture, Thomas Jefferson University, Cardeza Library.

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

The University of Texas M. D. Anderson Cancer Center, Conference on Tumor Markers: Discovery to Practice, Santa Barbara, CA, Chair, 3/2003

Veridex L.L.C., 5th International Conference on Minimal Residual Disease, San Francisco, CA, Co-Chairman, 9/2005

The University of Texas M. D. Anderson Cancer Center, Tumor Markers for Personalized Medicine: The New Frontier, Symposium, Kona, HI, Chair, 3/2006

NIH, Tumor Dormancy Workshop: Tumor Cell Dormancy Think Tank Challenges and Research Opportunities, Bethesda, MD, Chair, 6/2006

The University of Texas M. D. Anderson Cancer Center, First International Inflammatory Breast Cancer Conference, Houston, TX, Chair, 12/2008

UT Health Science Center at San Antonio School of Educational Programs, CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, Chair, 12/2008

AIM Group, 1st International Meeting on New Drugs in Breast Cancer, Rome, Italy, Chair, 4/2009

Veridex LLC, Veridex Dinner Program Meeting during ASCO, Orlando, FL, Chair, 5/2009

University of Athens, 7th International Congress on Minimal Residual Cancer – Scientific Committee Member, Session III: CTCs and DTCs as tumor biomarkers, Athens, Greece, Chair, 9/2009

The University of Texas M. D. Anderson Cancer Center, Founder of the IBC World Alliance Meeting, San Antonio, TX, Chair, 12/2009

2nd International Conference on IBC- Scientific Committee, Marseille, 10/2010

3rd International Conference on IBC, co-Chair, Philadelphia, 12/2012

Kimmel Cancer Center Breast Symposium, March 2014 : Chairman and Founder.

Co-Chair- 5th International Conference on IBC, Boston, 7/16

Co- Chair- 1st OncoSET Precision Medicine Conference, 4/17

Co-Chair- 2nd OncoSET Precision Medicine Conference 5/18

Co-Chair- 6th International Conference on IBC, Madrid, Spain, 9/18

Presentations at National or International Conferences (not updated)

Invited:

Electrorotation characterization of breast cancer cell lines (MCF-7, MCF-7 neo-3, MCF-HER2-18), Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, 5/1998

p53, HER-2/neu, and serial MDR protein expression in inflammatory breast cancer, 10th International Congress on Senology (Breast Diseases), Senologic International Society, Lisbon, Portugal, 5/1998

Electrorotation reveals dielectrophoretic variations related to HER-2/neu overexpression in breast cancer cell lines, 4th International Symposium on Predictive Oncology and Therapy, Nice, France, 10/1998

An integrated multimodality approach to the treatment of inflammatory breast cancer: Prognostic implications of paclitaxel treatment and p53 status, 21st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/1998

Chemotherapy in early breast cancer, 1st Annual Palm Beach Cancer Symposium, Boca Raton, FL, 2/1999

The prognostic value of tumor size in axillary node-negative breast cancer: A retrospective analysis of breast cancer patients treated at The University of Texas M. D. Anderson Cancer Center with >10 years follow up, Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, 5/1999

Clinico-pathological characteristics of breast cancer associated with thyroid disease, 10th European Cancer Conference, Vienna, Austria, 9/1999

Magnetic resonance imaging for evaluation of clinical response to induction chemotherapy in locally advanced breast cancer, 4th Annual Breast Cancer Conference, The Susan G. Komen Breast Cancer Foundation, Washington, DC, 9/2000

The medical management of primary and metastatic breast cancer, UT Southwestern Medical School, Dallas, TX, 3/2001

The role of anthracyclines in the management of breast cancer, Arden Hills Country Club (Sponsored ACS), Sacramento, CA, 4/2001

Medical management of advanced breast cancer and new treatments for breast cancer, 5th International Colloquium of Oncology and Hematology, Oaxaca, Mexico, 6/2001

New trends in the adjuvant treatment of breast cancer, Rhode Island Hospital, Rhode Island, NJ, 6/2001

Anthracyclines in the management of breast cancer: A systematic review, Texas Tech Medical School/Southwest Cancer Center, Lubbock, TX, 9/2001

The medical management of primary breast cancer, The Alabama Cancer Congress, Pensacola, FL, 10/2001

Weekly high-dose paclitaxel has significant antitumor activity in inflammatory breast cancer, 11th European Cancer Conference, Lisbon, Portugal, 10/2001

Adjuvant therapy in breast cancer: Current options and future trends, Short Hills Hilton, Newark, NJ, 11/2001

Adjuvant therapy in breast cancer: Current options and future trends, Caffee on the Green, Bayside, NY, 11/2001

Randomized inflammatory breast cancer, American College of Surgeon Oncology Annual Meeting, Chicago, IL, 11/2001

New frontiers in the management of primary and metastatic breast cancer, Grand Rounds, Beth Israel Hospital-Harvard Medical School, Boston, MA, 3/2002

The evolution in the medical management of primary breast cancer, Grand Rounds, Henry Ford Hospital, Detroit, MI, 3/2002

The role of maspin and laminin-5 as novel prognostic markers in axillary node-negative (ANN) breast cancer, 38th Annual ASCO Meeting, American Society of Clinical Oncology, Orlando, FL, 5/2002

The evolution in the medical management of primary breast cancer, The University of South California, Los Angeles, CA, 6/2002

Paclitaxel significantly improves the prognosis in inflammatory breast cancer: The M. D. Anderson Cancer Center Experience (1974-2000), 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2002

Paclitaxel significantly improves the prognosis in inflammatory breast cancer: The M. D. Anderson Cancer Center Experience (1974-2000), San Antonio Breast Cancer Highlights Meeting, NOCR, New Orleans, LA, 1/2003

Tumor markers: Discovery to practice, Tumor Marker Conference, Santa Barbara, CA, 2/2003

A phase II study of Imatinib in metastatic breast cancer, CTEP Early Drug Development Spring 2003 Meeting, NIH, Bethesda, MA, 3/2003

Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer, 94th Annual AACR Meeting, American Association of Cancer Research, Washington, DC, 7/2003

Thyroid hormones and breast cancer: Primary hypothyroidism is associated with a reduced incidence of primary breast cancer, 94th Annual AACR Meeting, American Association of Cancer Research, Washington, DC, 7/2003

A Phase II, multicenter, randomized trial of Bevacizumab (Avastin) with or without neoadjuvant weekly paclitaxel and adjuvant doxorubicin, cyclophosphamide in patients with primary operable breast cancer, American College of Surgeon Oncology Annual Meeting, Miami, FL, 1/2004

New advances in the treatment of breast cancer, 4th Annual Cancer Institute Symposium – Cancer Updates: Advances in prevention, diagnosis and treatment, Springfield, IL, 2/2004

Advexin (ad5CMVp53) combined docetaxel (T) and doxorubicin (D) as induction chemotherapy (IC): Significant efficacy of a novel gene-therapy approach for patients with locally advanced breast cancer, 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2004

Detection of circulating tumor cells is a prognostic factor in first-line metastatic breast cancer, 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2004

Imatinib mesylate (Gleevec) suppresses interferon-gamma production by activated CD4 T cells of patients with metastatic breast cancer, 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2004

Inflammatory breast cancer challenges in diagnosis and treatment, GSK IBC Investigator' Meeting, GlaxoSmith Kline, San Antonio, TX, 12/2004

Predictive and prognostic tools for managing metastatic breast cancer-prognostic and predictive value of circulating tumor cells in metastatic breast cancer: Clinical applications and research opportunities, San Antonio Breast Cancer Conference - Satellite Symposium, San Antonio, TX, 12/2004

Circulating tumor cells in breast cancer: Challenges and opportunities for the detection of microscopic disease, 13th Annual Radiation Workshop, Round Top, TX, 4/2005

Presence of circulating tumor cells in metastatic breast cancer predicts rapid progression, Annual ASCO 2005 Meeting, American Society of Clinical Oncology, Orlando, FL, 5/2005

Circulating tumor cells as prognostic markers in metastatic breast cancer, Retreat of the Breast Cancer Intergroup of North America (TBCI) Meeting, Chicago, IL, 6/2005

Predicting overall survival and progression-free survival in metastatic breast cancer, Educational Dinner Meeting for Medical Oncologists, Dallas, TX, 6/2005

Circulating tumor cells, disease progression, and survival in metastatic breast cancer, Lilly Breast Opinion Summit Meeting, Eli Lilly, Lisbon, Portugal, 9/2005

Circulating tumor cells: A prognostic or predictive factor?, 5th International Symposium on Minimal Residual Cancer, San Francisco, CA, 9/2005

Clinical application of circulating tumor cells in breast cancer, 43rd Annual Meeting of the Japan Society of Clinical Oncology Luncheon Seminar, Nagoya Congress Center, Nagoya, Japan, 10/2005

Cell search technology, Tumor Board Staff Meeting, St. Catherine of Siena Medical Center, Smithtown, NY, 11/2005

Evaluation of therapeutic results: Relative values of tumor markers, imaging studies and detection of circulating tumor cells in clinical practice, Veridex Satellite Symposium, Veridex L.L.C., San Antonio, TX, 12/2005

Trastuzumab-based regimens in primary breast cancer: Targeted therapy and beyond, XXIII Annual Meeting of the National Cancer Institute of Mexico (INCAN), Puerto Vallarta, Mexico, 2/2006

Prognostic and predictive role of circulatory tumor cells in breast cancer, Tumor Markers for Personalized Medicine: The New Frontier Symposium, Kona, HI, 3/2006

Chemotherapy regimens today, American Society of Breast Disease: 30th Anniversary Symposium, Las Vegas, NV, 4/2006

Metastatic breast cancer: Circulating tumor cells, Challenging Cases in Breast Cancer - Meeting, New Orleans, LA, 4/2006

Circulating tumor cells in metastatic breast cancer: Biological value beyond tumor burden, 42nd Annual ASCO Meeting, American Society of Clinical Oncology, Atlanta, GA, 6/2006

Circulating tumor cells, Biological Basis of Breast Cancer Conference, San Diego, CA, 7/2006

Maximizing metastatic breast cancer treatment and outcomes through cell-based disease monitoring and anemia management, Tumor Board Meeting, Bay Medical Regional Cancer Center, Panama, FL, 8/2006

Maximizing metastatic breast cancer treatment and outcomes through cell-based disease monitoring and anemia management, Breast Cancer Grand Rounds Dinner Meeting, Panama, FL, 8/2006

Maximizing metastatic breast cancer treatment and outcomes through cell-based disease monitoring and anemia management, Grand Rounds Meeting, Northwestern Memorial Hospital, Chicago, IL, 8/2006

Microscopic disease in breast cancer: Clinical applications and research opportunities, International Scientific Symposium IGF-MD Anderson, IGF, Paris, France, 9/2006

New technologies for tumor cell detection in blood and bone marrow, 31st ESMO Congress, Istanbul, Turkey, 10/2006

A phase II combination study of lapatinib (TYKERB®) and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC), 29th San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2006

Inflammatory breast cancer (IBC): Patterns of recurrence and micrometastatic homing, 29th San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2006

Inflammatory breast cancer update, Grand Rounds, M. D. Anderson Cancer Center, Orlando, FL, 1/2007

Molecular therapies of cancer, Academy of Molecular Imaging (AMI) Meeting, American Society of Nuclear Cardiology, Miami Beach, FL, 1/2007

The complexity of inflammatory breast cancer (IBC): The M. D. Anderson Cancer Center Mission, Palm Beach Event, Cancer Seminar, The University of Texas M. D. Anderson Cancer Center, Palm Beach, FL, 2/2007

Circulating tumor cells, Strategic Planning Meeting on Biomarkers for Plk1 Inhibitors, Boehringer Ingelheim, Vienna, Austria, 3/2007

Circulating tumor cells (CTCs) in breast cancer patients: Prognosis, prediction and beyond, Grand Rounds, Dartmouth Hitchcock Medical Center, Lebanon, NH, 3/2007

Inflammatory breast cancer, 32nd Congress AMHOQ, Quebec, Canada, 5/2007

Emerging approaches with circulating tumor cells, 6th Annual International Congress on the Future of Breast Cancer, Physician Education Resource (PER), Kohala Coast, HI, 7/2007

Cell search experience, Research Meeting on Cell Search, Dr. Colin Curran, Practice, Spartanburg, SC, 8/20/2007

Circulating tumor cells in metastatic breast cancer: Toward personalized treatments, 6th International Symposium on Minimal Residual Cancer, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 9/21/2007

Circulating tumor cells (CTCs): Toward personalized therapy in breast cancer, Cell Search Assay: Breast Cancer, University of Miami Sylvester Cancer Center, Miami, FL, 10/3/2007

Inflammatory breast cancer: Diagnostic and therapeutic challenges, The Visiting Speakers Program in Oncology, Universite de Montreal, Montreal, Canada, 11/2007

Lapatinib/Paclitaxel for inflammatory breast cancer, Chemotherapy Foundation Symposium XXV, Mount Sinai School of Medicine, New York, NY, 11/2007

Circulating tumor cells (CTCs) and prognostic stratification in metastatic breast cancer (MBC): Need for a modification of the AJCC staging system?, 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2007

HER-2 positive inflammatory breast cancer: High pathological response rate with trastuzumab-based neoadjuvant therapy, 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 12/2007

Circulating tumor cells, RTOG Semi-Annual Meeting, Radiation Oncology Group, San Diego, CA, 1/2008

Circulating tumor cells as predictive and prognostic markers, 1st Annual North American Symposium on Personalized Therapies for Breast Cancer, The Oncology Learning Center, Miami, FL, 1/2008

Targeting inflammatory breast cancer, Tumor Conference, Halifax Medical Center, Daytona Beach, FL, 2/2008

Circulating tumor cells in breast cancer therapy, Breast Cancer Program, Roswell Park Cancer Institute, Buffalo, NY, 3/2008

Inflammatory breast cancer: Defining biology and novel therapies, Morning Speakers Bureau Meeting, University of New Mexico, Albuquerque, NM, 3/2008

Inflammatory breast cancer: Diagnostic and treatment challenges, Grand Rounds, Presbyterian Healthcare Hospital, Albuquerque, NM, 3/2008

A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor positive metastatic breast cancer, 44th Annual Meeting of the American Society of Clinical Oncology, American Society of Clinical Oncology, Chicago, IL, 5/2008

Circulating tumor cells, Biological Basis in Breast Cancer Conference, CBCE, San Francisco, CA, 7/2008

New frontiers in micrometastasis research: A transatlantic perspective, Transatlantic Research and Innovation Symposium on Cancer, Carnegie Institute, Washington, DC, 10/2008

Inflammatory breast cancer: A special tumor entity?, Meet the Professor: Advanced Course on Breast Cancer, Accademia Nazionale di Medicina, Modena, Italy, 11/2008

HER-negative breast cancer: Biology and therapeutic challenges, Merck Oncology Breast Cancer Strategy Committee Meeting, Merck Oncology, Upper Gwynedd, PA, 3/2009

The biological information obtainable from circulating tumor cells, 11th International Conference Primary Therapy of Early Breast Cancer, St. Gallen Oncology Conferences, St. Gallen, Switzerland, 3/2009

Bevacizumab: New schedules and new combinations, 1st International Meeting on New Drugs in Breast Cancer, AIM Group, Rome, Italy, 4/2009

Circulatory tumor cells in metastatic breast cancer: Site-specific risk stratification and HER-2 determination, opportunity for targeted therapeutics, Veridex Dinner Meeting, Veridex LLC, Orlando, FL, 5/2009

Systemic therapies for IBC: From chemotherapy to targeted therapies: State of the art and future perspectives, AIOM Inter-Regional Conference, AIOM, Cagliari-Villasimius, Italy, 5/2009

Minimal burden to breast cancer: How to approach, 11th Milan Breast Cancer Conference, IEO European Institute of Oncology, Milan, Italy, 6/2009

The potential role of circulating tumor cells, Breast Cancer: Current Controversies and New Horizons Conference, Harvard Medical School, Boston, MA, 7/2009

Circulating tumor cells in breast cancer: Advanced tools for tailored therapy?, 7th International Congress on Minimal Residual Cancer, University of Athens, Athens, Greece, 9/2009

Clinical utility of circulating tumor cells, Circulating Tumor Cells: Detection, Diagnostics, Prognostics and Treatment Conference, National Cancer Institute at Frederick, Bethesda, MD, 9/2009

Inflammatory breast cancer: Finding a cure by achieving early detection and treatment, CSG WEST 62nd Annual Meeting - Health Forum, Council of State Governments-WEST, Santa Fe, NM, 10/2009

Systemic approaches to inflammatory breast cancer, 11th Annual Lynn Sage Breast Cancer Symposium, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, 10/2009

Inflammatory breast cancer: Biology and treatment, Meet the Professor 5th Advanced Course on Breast Cancer, Accademia Nazionale di Medicina, Modena, Italy, 11/2009

Circulating tumor cells directed therapies in metastatic breast cancer, Roche CTC Meeting during San Antonio Breast Cancer Symposium, Roche Products Limited, San Antonio, TX, 12/2009

CTCs in breast cancer: Advanced tools for tailored therapy? Methods workshop speaker, 2010 Annual Meeting of the American Association for Cancer Research, Washington, DC, 4/2010

Circulating tumor cells (CTCs) in breast cancer: Use of novel diagnostics to define the metastatic process. CHI Biomarker World Congress 2010, Philadelphia, PA, 5/2010

Inflammatory breast cancer (IBC): Diagnosis, biology and treatment. Helen Graham Cancer Center, Newark, DE, 5/2010

Circulating tumor cells (CTCs) in breast cancer: From bedside to bench and forward to personalized therapy. AstraZeneca Weekly Oncology Conference, Wilmington, DE, 6/2010

Creating a state-of-the-art comprehensive breast center to improve patient care, enhance workflow and efficiency. Keynote Speaker, ACI Breast Centers of Excellence Conference, Philadelphia, PA, 6/2010

Inflammatory and locally advanced disease, Speaker and Session Chair, 4th International Consensus Conference on Neoadjuvant Treatment of Primary Breast Cancer, Biedenkopf, Germany, 9/2010

Medical treatment of IBC: Present & Future, 2nd International Inflammatory Breast Cancer Conference, Marseille, France, 10/2010

Circulating tumor cells and their prognostic and predictive value in breast cancer, VIII GEICAM International Symposium, A Coruna, Spain, 3/2011.

The prognostic and predictive value of enumeration and molecular characterization. ADAPT/2nd Annual Circulating Tumor Cells Conference, Philadelphia, PA, 9/2011

Circulating tumor cells: Where are we? 2nd International Meeting on New Drugs in Breast Cancer, Rome, Italy, 10/2011

Lapatinib: New prospectives in early breast cancer. 2nd International Meeting on New Drugs in Breast Cancer, Rome, Italy, 10/2011

CTCs: Evolving concepts for personalized therapy in breast cancer. National Medical Oncology Conference, Bologna, Italy, 11/2011

Prognostic and predictive value of enumeration and molecular characterization. Speaker, Session Chair and Scientific Advisory Board Member. Molecular Med Tri-Con/Annual Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment Meeting, San Francisco, CA, 2/2012

Evolving concepts in the management of metastatic breast cancer. 1st Joint Conference KFSHD-RPCI-SCF-ASCO on Management of Colon, Breast and Lung Cancer: Update and Future Prospects, Dammam, Saudi Arabia, 3/2012

Einstein Hospital-Montifiore New York, NY- Grand Rounds 4/3/2013.

ASCO Annual Meeting, Chicago, IL. “Beyond Trastuzumab and Lapatinib-New Options in HER2 Positive Breast Cancer.” 5/31/2013. “Adjuvant Chemotherapy of Breast Cancer Improving Patient Selection and Understanding Benefits and Risks”

China 88 Xintiandi Shanghai. Defining the role of circulating tumor cells (CTCs) in the liquid phase of epithelial tumors.” Immunican Shanghaie Conference . Fudan Hospital./ 9/2013.

San Paulo Agendia Talk. Presentation with Dr. Buzaid of Hospital San Jose in Sao Paulo. II Simposio Oncoclinicas Do Brasil: Abordagem Multidisciplinar dos tumores Mama. Neoadjuvant Treatment- Practical Aspects. 9/21/2013. Brazil.

9th International Symposium on Minimal Residual Cancer (ISMRC 2013) **EMT and CTC**. Paris, France. 9/21/2013.

5th Symposium Primary Systemic Treatment in the Management of Operable Breast Cancer. Cremora Italy. Workshop on Circulating Tumor Cells in Routine Clinical Setting. 10/3/2013.

PBCC Workshop Presentation: Conference. Harrisburg, PA 10/15/2013.

Duke Round Table Meeting. North Carolina. 10/22/2013

Facing Breast Cancer: New Advances in the Treatment of IBC. Radiation Fellows Lecture. 10/31/2013.

3rd International Meeting on New Drugs in Breast cancer. Rome, Bastianelli Congress Center. November 13-15, 2013.

San Antonio Breast Symposium. “Inflammatory Breast Cancer Diagnosis, Treatment and Biology”. December 10th-12th. 2013

4th IBC Conference-Belgium. IBC Meeting AntWerp 2014. HER2 Directed Therapy. Ongoing Clinical Trials in IBC. 5/6/2014.

ASCO Breast Cancer Tumor Markers Expert Panel, ASCO, Chicago IL . 5/28/2014. CTC molecular monitoring in HR-MBC treated with a combination of aromatase Inhibitor and everolimus(Afinitor) Novartis. 6/1/2014.

16th Milan Breast Cancer Conference. Innovation in Care and Research. Umberto Veronesi, Chairman 6/26/2014.

San Paolo, Brazil. Agendia Presentation: Neoadjuvant chemotherapy for inflammatory breast cancer. 7/25-26/2014

2014 Annual Meeting of CSCO Xiamen, China. Improve Standardized Treatment Level, Broaden International Prospective. New Targeted Therapy in Breast Cancer. 9/18/2014.

Circulating Tumor Cells in Cancer Patients Management. Venice, Italy. 9/22/2014.

2nd International Symposium ACTC. Advances in Circulating Tumour Cells from Basic Research to Clinical Practice. “CTC in breast cancer 2004-2014: Clinical Value Revisted” Rethymnon, Crete, Greece.

18th SIS 2014 World Congress on Breast Healthcare, on behalf of Agendia. Orlando, Florida. 10/17/2014.

2014 San Antonio Breast Cancer Symposium. 12/9/-12/132014.

2015 CellSearch Ad Board China Janssen Diagnostics April 11 2015

2015 April 23-26, Birmingham United Kingdom, IBC Symposium presentation

2015. June 12: Hosting: Inaugural Jefferson Inflammatory Breast Cancer Community Conference. Thomas Jefferson University. Phila. PA

Other, Including Scientific Exhibitions

Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib with placebo in combination with tamoxifen or anastrozole in hormone receptor-

positive metastatic breast cancer, 45th Annual Meeting of the American Society of Clinical Oncology, American Society of Clinical Oncology, Orlando, FL, 5/2009

Merck Breast Cancer Scientific Input Engagement. Baltimore, MD. 4/5/2014

Seminar Invitations from Other Institutions

New biomarkers and circulating cells, VI Madrid Breast Cancer Conference, Madrid, Spain, 6/1/2005

The role of MNR for diagnosis and follow up, VI Madrid Breast Cancer Conference, Madrid, Spain, 6/1/2005

Inflammatory breast cancer: Update on the diagnosis, epidemiology, biology and treatment, Temple University Dept. of Biology Special Seminar, Philadelphia, PA 11/2011

Circulating Tumor Cells (CTCs): Prognostic Value Biomarker Analysis and Personalized Therapy. Grand Rounds, Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, 12/2011

CTCA. Cancer Treatment Centers of America. Atlanta Georgia. IBC Symposium. 5/2015.

Presentation: Inflammatory Breast Cancer(IBC): Novel Insights into an old disease and The Future Treatment of IBC.

Lectureships and Visiting Professorships

Medical management of advanced breast cancer and new treatments for breast cancer, 5th International Colloquium of Oncology and Hematology, Oaxaca, Mexico, 6/2001

Molecular targets in breast cancer: Current status and future directions, International Cancer Congress, Rovigo, Italy, 12/2001

Angiogenesis inhibitors in cancer research, Audio Teaching Program, Albert Einstein College of Medicine, Houston, TX, 8/2002

Molecular targets in breast cancer, International Cancer Center of Rovigo, Rovigo, Italy, 10/2002

The current approach to patients with inflammatory breast cancer, European Institute of Oncology (IEO), Milan, Italy, 6/2008

Circulating tumor cells: Novel avenue to personalized therapy in breast cancer, AstraZeneca Oncology, Sheffield, United Kingdom, 9/2008

Inflammatory Breast Cancer (IBC): Challenges and Opportunities in the Diagnosis, Biology and Treatment, Connolly-Zaniboni Visiting Professor in Breast Cancer, Tufts Medical Center, Boston MA, 11/2010

Circulating tumor cells, London Regional Cancer Program Translational Breast Cancer Research Unit and the CIHR Strategic Training Program in Cancer Research and Technology Transfer, Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit Seminar Series, London Health Sciences Centre, London, Ontario, Canada, 4/2011.

Other Presentations at State and Local Conferences

Treatment of locally advanced and inflammatory breast cancer, Preceptorship Program for Schering-Plough at The University of Texas M. D. Anderson Cancer Center, Schering-Plough Pharmaceuticals, Houston, TX, 9/2002

Treatment of locally advanced and inflammatory breast cancer, Preceptorship Program for Schering-Plough at The University of Texas M. D. Anderson Cancer Center, Schering-Plough Pharmaceuticals, Houston, TX, 10/2002

Promising target therapies for breast cancer, Fellows Program, University of Texas Medical Branch, Galveston, TX, 1/2005

Circulating tumor cells (CTC) as prognostic factor in metastatic breast cancer (MBC), Southwest Oncology Group Meeting, Southwest Oncology Group, Dallas, TX, 10/2005

Circulating tumor cells, Breast Cancer Research Group Retreat, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2005

Systemic therapy for primary breast cancer, chemotherapy adjuvant, neoadjuvant, and biologic therapy, Nurse Lecture, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2005

Evaluation of therapeutic results: Relative values of tumor markers, imaging studies and detection of circulating tumor cells in clinical practice, Satellite Symposium, Veridex LLC, San Antonio, TX, 12/2005

Measurement of markers of disease activity in breast cancer: Current status and use of markers, CellSearch assay and use in breast cancer, KOL Advisory Board Meeting, CellSearch System KOL, Dallas, TX, 12/2005

Breast cancer management, Cyfair Cancer Center, Houston, TX, 11/2006

Circulating tumor cells in metastatic breast cancer: Standard prognostic Factors and what else?, Breast Cancer Clinical Research Meeting (BCCR), The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2/16/2007

Circulating tumor cells, Preceptorship Program for Spanish Oncologists, Trevisio, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 3/2007

Inflammatory breast cancer (IBC): Challenges in diagnosis and treatment, Annual Education Conference (AEC), Case Management Society of America, Houston, TX, 9/26/2007

Molecular classification of breast cancer and its application to prognostic and selection of treatment, 2nd Annual Metastatic Breast Cancer Network Conference, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 11/2007

Inflammatory breast cancer: Challenges, diagnosis and treatment, Philippine Nurse Association of Metropolitan Houston Spring Seminar, The Philippine Nurses Association of Metropolitan Houston, Houston, TX, 5/2008

Inflammatory breast cancer: What you don't know may kill you, 36th Annual Physician Assistant Conference, American Academy of Physician Assistants, San Antonio, TX, 5/2008

Inflammatory breast cancer (IBC): Challenges and opportunities, Pilot International Media Day, The University of Texas M. D. Anderson Cancer Center, Public Affairs, Houston, TX, 6/2008

Inflammatory breast cancer research program and the evolution of multidisciplinary research: Back from the future?, Advances in Oncology Institutional Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2008

Circulating tumor cells in metastatic breast cancer: The microscopic revolution, Breast Cancer Research Program Fall Retreat, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 10/2008

Circulating tumor cells in metastatic breast cancer: The microscopic revolution, Breast Cancer Research Program Fall Retreat, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 10/2008

Circulating tumor cells: Novel path to targeted therapies in breast cancer, Translational Biology and Molecular Medicine Graduate Program Seminar Series, Baylor College of Medicine, Houston, TX, 10/2008

Inflammatory breast cancer (IBC): Myths and reality, 9th Annual Texas Conference for Women, Governor Rick Perry and First Lady Anita Perry, Houston, TX, 10/2008

Inflammatory breast cancer: The path to personalized therapy, The Division of Cancer Medicine Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2008

Novel targeted therapies in inflammatory breast cancer, First International Inflammatory Breast Cancer Conference, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 12/2008

Inflammatory breast cancer: State of the art and future perspective, Medical Oncology Fellowship Class, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 5/2009

Inflammatory breast cancer: Finding a cure by achieving early detection and treatment, CSG-WEST 62nd Annual Meeting Health Forum, Council of State Governments - WEST, Santa Fe, NM, 10/2009

Systemic therapies for IBC: From chemotherapy to targeted therapies: State of the art and future perspective, Grand Rounds Meeting, Christus St. John Hospital, Nassau, TX, 10/2009

Evolving strategies in the management of inflammatory breast cancer, 29th Annual UCSF Clinical Cancer Update, Lake Tahoe, CA, 1/2010

Adjuvant hormonal therapy, Highlights of the 2009 San Antonio Breast Cancer Symposium, Fox Chase Cancer Center, Philadelphia, PA, 2/2010

Inflammatory breast cancer: Clinical advances in women's cancers Session, Oncology Practice Reviews, Philadelphia, PA, 7/2010

Inflammatory breast cancer. PA Breast Cancer Coalition Annual Conference, Harrisburg, PA, 10/2010

Circulating tumor cells/Stem cells, Highlights of the 2010 San Antonio Breast Cancer Symposium, Fox Chase Cancer Center, Philadelphia, PA, 1/2011

Inflammatory breast cancer workshop. PA Breast Cancer Coalition Annual Conference, Harrisburg, PA, 10/2011

Metastatic breast cancer: Assessing clinical trials. Living Beyond Breast Cancer Community Meeting, Conshohocken, PA, 12/2011

Inflammatory Breast Cancer. Einstein Montefiorre NY, April 3, 2013

CAPERS Oncology Conference "Breast Cancer Update. Thomas Jefferson University. April 24, 2013
Cancer Biology Workshop Drexel University College of Medicine. June 17, 2013.

PBCC Workshop Presentation: PA Breast Cancer Coalition Conference. Harrisburg, PA October 15, 2013.

Facing Breast Cancer Series: New Advances in the Treatment of IBC: Thomas Jefferson University, Phila. PA October 31, 2013.

Breast Symposium of Thomas Jefferson University; Organized by Massimo Cristofanilli. April 25, 2014.

Nurse Navigators Presentation. Thomas Jefferson University. "Pregnancy and Breast Cancer". May 9, 2014.

2015 April 9, CTCA Atlanta Georgia, IBC Presentation

2015. 5/16/15. SBUR/SUO Joint Session, New Orleans Morial Convention Center, May 16th, 2015
"Circulating Tumor Cells: Telling the truth about metastases.

2015. ASCO Annual Meeting.

UNIQUE ACTIVITIES

CBS media interview on protocol study ID00-008, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/2002

T.V. interview to write a story about the Breast Center Clinic and ongoing inflammatory breast cancer research. Interviewed by Leslie Mouton, Health Reporter at KSAT, the ABC affiliate in San Antonio,

The University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/2008

On-camera interview on inflammatory breast cancer, at the Breast Center, UT M. D. Anderson Cancer Center, Houston, TX. Interviewed by Cassandra Floyd, Senior Health Care Producer, Critical Information Network, LLC, 11/2008

On-camera interview for news release on M. D. Anderson Patient Paints Gulf Coast Cities Pink to Raise Awareness of Inflammatory Breast Cancer. Interviewed by Tomise Martin, External Communications Office, UT M. D. Anderson Cancer Center, Houston, TX, 10/2009

Volunteered for KRPC Channel 2 phone bank to educate the community about inflammatory breast cancer.

Stories run in every newscast, KPRC, Houston, TX, 10/2009.

Interview with Andy Pollack from New York Times March 12, 2014”Sidestepping The Biopsy with New Tools to Spot Cancer”.

Interview with WHYY TV with Taunya “Genomic Testing” March 11, 2014

CAPERS Oncology Conference: Breast Cancer Update – Blumble building
Oncology Nursing conference. 4/24/2013

Opening Event for Women’s Speciality Clinic at Jefferson’s Breast Cancer Center. Master of Ceremonies. 5/10/2013.

Press Conference. Instuto Superiore di Sanita (NIH), Viale Regina Elena 299. Rome. 11/13/2013.

DAVA Oncology: Video for Celgene. 1/30/2014.

Philadelphia Magazine. THINKPINK insert. Interview and picture for October 2014.

WHYY Interview March 11, 2014: Genomic Testing with Ann Meredith

NY Times Interview with Andy Pollack: March 12, 2014.

Guardant Health Video: May 14, 2014.

HemOnc Interview June 18, 2014

Philadelphia Magazine Top Doc 2015

Susan B. Komen Race for the Cure Sunday May 10th, 2015.

Interview for OncLive. Reporter at ASCO.

DATE OF LAST CV UPDATE

1/12/19

Massimo Cristofanilli, M.D., F.A.C.P.